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Abstract 
Alzheimer's disease (AD) is a neurodengerative disease that causes 
progessive cognitive and behavior deterioration. This disease is characterized by two 
histopathological hallmarks: the presence of neurofibrillary tangles (NFTs) and senile 
plaques. Formation of senile plaques is by deposition of amyloid P protein (A|3), 
which is proteolytic cleavage of the amyloid precursor protein (APP) by two unknown 
proteases: p- and y-secretase. These proteases are prime therapeutic targets. In 1999, 
P-secretase was independently cloned by four different research groups, and was 
named as beta-site APP-cleaving enzyme (BACE), memapsin 2 and membrane-bound 
aspartyl protease (Asp2). 
The present study was aimed at developing reliable screening assays for 
inhibitor of BACE. This involved the cloning of mouse and human BACE cDNAs 
with complete amino acid coding sequences, the soluble form of human BACE with 
deletion of transmembrane region and pre region which was designated as prohBACE, 
and the human BACE with deletion of transmembrane region as well as pre and pro 
region which was designed as nohBACE by polymerase chain reaction (PCR). These 
cDNAs were sub cloned into appropriate expression vectors. The proteins of mouse 
and human BACE containing the full coding sequences were successfully expressed 
in Chinese hamster ovary (CHO) cells transiently and stable cell lines overexpressed 
with mouse and human BACE in CHO cells have been established. The soluble form 
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of BACE, the prohBACE and nohBACE were also successfully expressed in E.coli., 
BL21(DE3)LysS cells. Bioactive recombinant BACE was purified by metal chelating 
chromatography. 
For assaying BACE activity, two methods were developed. The high 
performance liquid chromatography (HPLC) and the fluorescence resonance energy 
transfer (FRET). For HPLC analysis, two different peptide substrates were 
synthesized in-house. One was derived from Swedish mutation of APP with cleavage 
site of P-secretase which was demonstrated a better substrate for P-secretase, the other 
was derived from sequence of the wild type APP with the cleavage site of p-secretase. 
The proteolytic cleavage of these substrates by membrane extracts of CHO cells 
overexpressed with BACE or by purified recombinant BACE was measured by 
analytical reverse-phase high performance liquid chromatography (RP-HPLC). The 
activity of recombinant enzyme was also measured by a novel fluorometric assay with 
custom-made fluorogenic substrates. The fluorometric method was demonstrated to 
be suitable for high throughput screening of BACE inhibitors. 
Specific antibody against BACE was used as primary antibody in 
immunohistochemistry. Immunohistochemical characterization of this antibody 
demonstrated that specific immunoreactive staining was found in CHO cells stably 
over-expressed with mouse and human BACE but not with non-transfected CHO cells. 
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The BACE immunohistochemistry was found concentrated in the cytoplasm and in 






楚的蛋白酶（P- and Y-蛋白酶）對方令澱、粉樣蛋白前體(APP)的剪切而形成。這 
些蛋白酶是治療老年痴呆症的主要目標。在1999年，P-蛋白酶由四個不同的硏 
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Chapter 1 Introduction 
Chapter 1 
Introduction 
1.1 Alzheimer's disease 
1.1.1 History of Alzheimer's disease 
Senile dementia, the loss of memory and other intellectual properties that 
commonly occur in the elderly, was first recognized in the time of Hippocrates (B.C. 
460-B.C. 370). The dementia begins at age 65 or older and progresses slowly and was 
considered as an inevitable accompaniment of aging. 
In 1906, a German psychiatrist named Alois Alzheimer (1864-1915) presented 
his findings on what was first called presenile dementia. One of his patients died at 
the age of 56 because of complete dementia. By examination of the autopsy of the 
brain of this woman, Alzheimer found not only the deposition of senile plaques that 
were commonly found in the brains of people with senile dementia but also the 
presence of neurofibrillary tangles - the thick, coiled fibers within the cytoplasm of 
the cerebral cortical neurons. This case was different from classical pathology of 
senile dementia because of the occurrence at relative young age, the rapid 
deterioration of the disease's progression, and the neuropathological findings. The 
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disease was subsequently named Alzheimer's disease in honor of his contribution. 
(Alzheimer, 1907) 
Alzheimer's disease was initially thought to be a rare condition affecting 
only young people, and was referred to as presenile dementia. Today late-onset 
Alzheimer's disease is recognized as the most common cause of the loss of mental 
function in those aged 65 and over. Alzheimer's diseases occur in people in their 30s, 
40s, and 50s, are called early-onset Alzheimer's disease. It occurs much less 
frequently, accounting for less than 10 percent of the estimated 4 million Alzheimer's 
cases in the United States. 
1.1.2 Definition of Alzheimer's disease 
Alzheimer's disease is the most common cause of dementia, characterized by a 
decline in intellectual functioning severe enough to interfere with a person's normal 
daily activities and social relationships. It is marked by progressive, irreversible 
declines in memory, performance of routine tasks, time and space orientation, 
language and communication skills, abstract thinking, and the ability to learn and 
carry out mathematical calculations (Esiri and Morris, 1997). Other symptoms of 
Alzheimer's disease include personality changes and impairment of judgment. The 
brains of patients with Alzheimer's have distinctive formations一abnormally shaped 
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proteins called tangles and plaques~that are recognized as the hallmark of the disease. 
Not all brain regions show these characteristic formations. The areas most 
prominently affected are those related to memory. 
As shown in Fig. 1-lA, plaques, or clumps of fibers, are formed outside the 
neurons in the adjacent brain tissue. A long-established plaque may be several 
hundred micrometers in diameter. The major component of senile plaques is now 
characterized as P-amyloid (Ap), a peptide of 39-43 amino acids, derived from 
proteolytic breakdown of a larger protein called the amyloid precursor protein. When 
Ap deposits are surrounded by abnormal neuronal processes called dystrophic neuritis, 
they form neuritic plaques. Ap also appears in diffuse plaques, which lack a central 
core and the corona of dystrophic neuritis. Diffuse and neuritic plaques are sometimes 
called senile plaques. Some authors think the diffuse plaque is the premature form of 
neuritic plaque (Esiri and Morris, 1997). In almost all cases of Alzheimer's disease, 
there is a mixture of diffuse and neuritic plaques, and in severe cases very large 
numbers of plaques are present. It is widely believed that the AP plaque is central to 
the pathogenesis of Alzheimer's disease, but the mechanism of Ap deposition is still 
unclear (Hardy and Higgins, 1992). In most cases, not only is amyloid deposited 
inside the plaque, but also along the walls of arteries in the cerebral cortex 
(congophilic angiopathy) (Esiri and Morris, 1997). 
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As shown in Fig. 1-IB, tangles are long, slender tendrils found inside nerve 
cells, or neurons. Scientists have learned that the tangles are mainly composed of a 
protein called tau that becomes structurally altered. The abnormal tau formation is 
now known to cause the characteristic tangles in the brain of Alzheimer's patients. In 
healthy brains, the tau protein provides structural support for neurons, but in 
Alzheimer's patients this structural support collapses. 
Scientists have found that tangles and plaques cause neurons in the brains of 
Alzheimer's patients to shrink and eventually die, first in the memory and language 
centers and finally throughout the brain. This widespread neuron degeneration leaves 
gaps in the brain's messaging network that may interfere with communication 
between cells, causing some of the symptoms of Alzheimer's disease. 
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Fig. 1-1 The major histopathological hallmarks of Alzheimer's disease seen on light 
microscopy. (A) A(3 deposited as diffuse and neuritic plaques in brain parenchyma. (B) 
neurofibrillary tangles within neuronal cell bodies (Bayer et al., 1999). 
5 
1.1.3 Symptoms of Alzheimer's disease 
Alzheimer's disease is characterized by damages of nerve cells in several 
regions of the brain. These regions include cerebral cortex, which involved in 
conscious thought and language; the basal forebrain, which has large numbers of 
neurons containing acetylcholine (ACh), a chemical important in memory and 
learning and the hippocampus, which is essential to memory storage. The earliest 
signs of Alzheimer's are found in the nearby entorhinal cortex 
1.1.3.1 Memory deficit 
AD is characterized by destroys of neurons in parts of the brain controlling 
memory, especially the hippocampus. There are two types of memory, the short-term 
memory (remembering for a few minutes or hours), and the long-term memory 
(remembering for a few years). In the early stage in Alzheimer's disease, the 
short-term memory is impaired but long-term memory is preserved. However, in the 
later stages, long-term memory is impaired. 
1.1.3.2 Difficulty in learning 
One of the earliest manifestations of Alzheimer's disease is the inability to 
acquire and retain new information and to integrate it with previously acquired 
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knowledge. This problem is partly the result of short-term memory impairment and 
can be readily observed in the difficulty the patient has in keeping abreast of recent 
developments in his or her profession and an inability to discuss current events. 
1.1.3.3 Language difficulties 
Alzheimer's disease's patient has damaged neurons in the cerebral cortex. 
The greatest damage occurs in areas of the cerebral cortex responsible for functions 
such as language and reasoning. At the early stage of disease, anomia occurs. Anomia, 
the inability to find the right word. The patient is aware of this deficit and may try to 
make up for them by using sentences to describe the object he cannot name 
(paraphrasia). As the disease progresses, agnosia sets in. Agnosia is more serious than 
anomia because, in addition to being unable to name an object, the person cannot 
identify it. For instance, he may not recognize a key; he may think it is a spoon and 
try to eat soup with it. 
1.1.3.4 Decline in ability to perform routine tasks 
Apraxia, the inability to carry out purposeful movements and actions 
despite intact motor and sensory systems, is evident early in the course of Alzheimer's 
disease. The more complex or technical skills, particularly those recently acquired or 
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requiring integration of various stimuli, are lost early in the process. The less complex 
actions, such as eating, walking, dressing, and undressing, tend to be reserved until 
the late stages. 
1.1.4 Prevalence of Alzheimer's disease 
Alzheimer's disease is the fourth leading cause of death of adults in USA, 
after heart disease, cancer and stroke (Lendon et al., 1997). However, the cost of 
treatment of Alzheimer's disease is much higher than the above-mentioned diseases. 
It is because it is a chronic disease, the duration of the disease is about 8 years after 
the diagnosis (Lendon et al., 1997) and huge amount of money is spent on residential 
and hospital care. AD is the most common cause of dementia among people age 65 
and older. Four million Americans currently suffer from the AD, and experts estimate 
that 22 million people around the world will be so afflicted by 2025 (Alzheimer's 
Disease Research Center, ADRC, 2002). The prevalence of AD doubles every 5 years 
beyond age 65. Prevalence is the number of people in a population with a disease at a 
given time. In fact, some studies indicate that nearly half of all people age 85 and 
older have symptoms of AD. 
AD is becoming a major public health concern. This is because life 
expectancy has increased dramatically since the turn of the century. More than 34 
8 
million people-13 percent of the total population of the United States-are age 65 and 
older. According to the U.S. Bureau of the Census, this percentage will climb to 18 
percent by the year 2025. 
1.2 Present treatment of Alzheimer's disease 
1.2.1 Acetylcholine and dementia 
Alzheimer's disease has been associated with loss of cholinergic nervous 
activity in the brain. Cholinergic nerves are so named because they use acetylcholine 
as their neurotransmitter. There is a dramatic loss of cholinergic cells within both the 
nucleus basalis and the medial septum of the AD brain as compared to aged matched 
controls (Whitehouse et al., 1982). Choline acetyltransferase (ChAT), the synthetic 
enzyme for acetylcholine, has been reported to be decreased 60-90% in the cerebral 
cortex and hippocampus of AD brains, (Davies and Maloney，1976), and there is a 
correlation between the extent to which cholinergic markers are decreased in cortical 
areas of the AD brain and the degree of cognitive impairments observed (Perry et al., 
1978). Acetylcholine is a critical neurotransmitter in the process of forming memories. 
Moreover, it is the neurotransmitter used commonly by neurons in the hippocampus 
and cerebral cortex—regions devastated by Alzheimer's disease. 
1.2.2 Tacrine as first drug approved by US Food and Drug Administration 
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Various drugs have been designed to inhibit acetylcholinestese (AChE), so 
as to increase the levels of ACh in the brain of AD patients, tacrine 
(9-amine-1,2,3,4-tetrahydroacridine) was the first drug approved for treatment. 
Tacrine is a centrally active noncompetitive AChE and butryl-ChE inhibitor that 
prevents the degradation of endogenously released ACh. The chemical structure of 
tacrine is shown in Fig. 1-2. 
MHj 
Fig. 1-2 Chemical structure of tacrine 
However, drugs inhibit AChE can only treat the symptoms of AD, but not 
the cure of it. Scientists investigated the biochemistry of two main hallmarks of AD 
brains, the senile plaques and neruofibrillary tangles that led to the development of 
two theories of AD pathophysiology. 
1.3 Proposed theory of Alzheimer's disease formation 
1.3.1 The amyloid cascade hypothesis 
1.3.1.1 The amyloid precursor protein 
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Cleavage of amyloid precursor protein (APP) by a-, |3- and y-secretase 
produced amyloid protein (A|3), which is responsible for the formation of amyloid 
plaques. (Glenner and Wong, 1984; Masters et al., 1985; Castano et al., 1986). APP is 
composed of 770 amino acids, and the gene of APP is on chromosome 21. It is a 
transmembrane protein. 
As shown in Fig. 1-3, the APP consists of a 17-residue signal peptide at the 
amino terminus (box with vertical lines). Two alternatively spliced exons of 56 and 19 
amino acids are inserted at residue 289; the first contains a serine protease inhibitor 
domain of the Kunitz type (KPI). A single membrane-spanning domain at amino acids 
700-723 (vertical hatched bar). The amyloid P-protein (Ap) fragment (white box) 
includes 28 residues just outside the membrane plus the first 12-14 residues of the 
transmembrane domain. 
APP is a glycoprotein and there are two potential glycosylation sites located 
at amino acid residues 542 and 571. 
1 17 289 C4P 571 ~~^ 770 
NH2 ^ ^ r t - g — 咖 � I 
Fig. 1-3. The largest APP of the known APP alternate transcripts. Regions of interest 
are indicated at their correct relative positions. 
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The APP is encoded by a single copy gene located at chromosome 21. 
Multiple transcripts of APP are formed by alternatively sliced transcripts, which, in its 
longest isoform, encode a single transmembrane spanning polypeptide of 695-770 
amino acids (Goldgaber et al., 1987; Kang et al., 1987; Tanzi et al, 1987; Robakis et 
al., 1988). It has been implicated in a variety of cellular processes and events. 
Secreted isoforms of APP (sAPP) containing a Kunitz-type protease inhibitor (KPI) 
consensus sequence that have a role in regulation of extracellular protease activity 
(Oltersdorf et al., 1989) and as inhibitors of protease involved in the regulation of the 
coagulation cascade (Smith et aL, 1990). The carboxyl-terminus of sAPP has been 
shown to be involved in regulating intracellular calcium levels and thus exerting 
neuroprotective activities (Mattson et al, 1993). 
1.3.1.2 The processing of amyloid precursor protein 
As schematically illustrated in Fig. 1-4, it is now becoming clear that the 
APP is processed through site-specific cleavages by at least three proteases, the a-, P-, 
and y-secretase. During the normal processing of APP, a-secretase cleaves within the 
sequence of Lys687 and Leu688 of APP that enables secretion of the large, soluble 
ectodomain of APP (a-APPs) into the medium and retention of the 83 residue 
carboxyl-terminal fragment ( � 1 0 kDa) in the membrane. The 10 kDa fragment can 
undergo cleavage by y-secretase at residue 711 or residue 713 to release the p3 
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peptides. 
It is hypothesized that AD is caused by abnormal processing of APP, which 
involves proteolytic cleavages, by |3- and y-secretase. P-secretase cleaves within 
sequence of Met671 and Asp672 of APP that results in the secretion of a truncated 
APPs (P-APPs) molecule and the retention of a 99 residue (�12kD) carboxyl-terminal 
fragment. The 12 kDa fragment undergoes cleavage by y-secretase at residue 711 or 
residue 713 to release the A(340 or A^42 peptides. 
Ap is a 4kD fragment of APP that constitutes the major component of 
plaques. It is 39-43 amino acids in length in AD brain (Glenner and Wong, 1984). 
Soluble Ap from normal cells is composed chiefly of Ap40 and insoluble Ap is 
composed mainly of A(342 (Dovey et al., 1993). In vitro study has shown that free Ap 
peptides cleaved from APP easily self-aggregate into highly neurotoxic amyloid 
fibrils (Pike et al., 1993). Ap42 aggregates much more rapidly than the most common 
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Fig. 1-4 Processing of APP by a-, P- and 丫-secretase. Cleavage of APP by a- and 
y-secretase to produce soluble APPa protein, a cytoplasmic protein, CTFa and a 
soluble protein, p3. Cleavage by p- and y-secretase to produce soluble APPp protein , 
a cytoplasmic protein, CTFp, Ap peptide. Abbreviation: CTF, carboxyl-terminal 
fragment (Hussain et al., 1999). 
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1.3.1.3 Neurotoxic effect of amyloid plaque 
The length of the C-terminal tail of A|3 is an important determinant of its 
readiness to aggregate into the amyloid fibrils (Yanker, 1996). It was found that the 
higher the ratio of Ap42 to Ap40, the higher the risk of developing amyloid fibrils. 
The accumulation and presumed neurotoxicity of Ap fibrils forms the basis of the 
amyloid cascade hypothesis of AD (Neve and Robakis, 1998; Hardy and Allsop, 
1991). According to the hypothesis, increased production of Ap42 leads to 
progressive extracellular deposition of fibrillar Ap42 around blood vessels and as 
diffuse and neuritic plaques, which in turn leads to disruption of neuronal homeostasis 
and progressive neuronal injury. This accumulation of neuritic plaques has two 
consequences: the first is inflammatory response (microglial activation and cytokine 
release, activation of complete cascade) and oxidative injury. The second is altered 
phosphatase activities, which leads to hyperphosphorylated tau protein, which leads to 
neurofibrillary tangles. Both consequences cause neuronal dysfunction and 
degeneration, with progressive cholinergic and other neurotransmitter deficits, which 
leads to dementia (Nagy et al., 1995). 
1.3.1.4 Genetic factors 
1.3.1.4.1 The amyloid precursor protein 
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There are substantial evidences that mutation of APP causes some forms 
familial Alzheimer's disease (FAD). The autosomal dominant mutations in APP that 
are associated with FAD cluster around the P_ and y- cleavage sites. A two-point 
mutation (the Swedish mutation) at amino acids 670 and 671 from Lys-Met to 
Asp-Leu is upstream of the P-cleavage site (Mullan, 1992) and results in a five- to 
eightfold increase in the formation of both AP40 and AP42 (Citron et al； 1992). The 
most simple explanation is that the Swedish mutation results in the over-production of 
the AP peptide and in particular, overproduction of long-tailed isoforms ending at 
residue 42 (Haass et al, 1994; Susuki et al,, 1994). Studies from a variety of groups 
suggested that AP, like several other amyloids, exhibits neurotoxicity when 
aggregated as a fibril, and implied that a conformational change is necessary to 
change the inert (or even marginally neurotrophic) soluble AP into toxic Ap (Lorenzo 
and Yanker, 1994). 
1.3.1.4.2 Apolipoprotein E (ApoE) 
ApoE is the major serum protein involved in cholesterol metabolism, 
transport and storage (Weisgraber et al., 1994). It is polymorphic and encoded by 
three alleles (ApoE-2, -3, -4), of which the ApoE-3 allele is the most common. 
Analysis of these polymorphisms in normal control populations and in patients with 
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AD has consistently shown that there is an increase in the frequency of the e4 allele in 
patients with AD (allele frequency in AD is approximately 40%) (Saunders et al., 
1993) There is no correlation between the presence of NFTs and a particular ApoE 
allele, whereas there is dose-dependent relationship between Ap and ApoE4 (Price 
and Sisodia, 1998). 
1.3.1.4.3 Presenilin genes 
St. George-Hyslop et al{\992\ Van Broeckhoven et al (1992) and Mullan 
(1992) presented evidence of location of a mutation responsible for early-onset 
familial Alzheimer disease on 14q, and was named as presenilins. Presenilins are 
transmembrane proteins. Presenilin-1 and presenilin-2 are encoded by genes on 
chromosome 14 and 1, respectively (Levy-Lahad et al,\995\ Sherrington et al., 1995), 
and are predominantly present in neurons (and to a lesser extent in glia) and its 
expression is closely associated with APP (Lee et al., 1996). One consequence ofPSl 
mutations is the enhanced production of AP42 (Borchelt et a/., 1996), suggesting that 
PSl mutations influence processing at the y-secretase site. Recent evidence suggests 
that activity of y-secretase require PSl and PSl could itself be the y-secretase 
(Strooper et al, 1998, Wolfe ^ ^ a/., 1999). 
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Fig. 1-5 Summary of the amyloid cascade hypothesis. Amyloid precursor protein (APP) 
is cleaved either by a-secretase resulting in the production of sAPPa, which might 
have a neuroprotective role, or by P-amyloid cleaving enzyme (BACE) and then 
y-secretase to yield Ap. The larger Ap42 peptides are more prone to self-aggregate 
and are thought to be more pathogenic (Mudher and Lovestone, 1999). 
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1.3.2 Tau and tangle hypothesis 
1.3.2.1 Tau protein 
Tangles are comprised of the microtubule associated protein called tau that 
is normally expressed in axons. In AD brain, the tau proteins become highly 
phosphorylated and aggregated into abnormal filaments in the cell body, known as 
paired helical filament (PHF). Tau protein belongs to a group of proteins known as 
microtubule-associated proteins (MAPs) with the function of modulating microtubule 
assembly, dynamic behavior and spatial organization (reviewed by Lee, 1993; 
Mandelkow and Mandelkow, 1995). Tau protein from adult human brain consists of 
six isoforms which all are phosphoproteins (Grundke-Iqbal et a/., 1986 ； Wood et al., 
1986). The degree of phosphorylation of tau protein regulates its biological activity. 
These proteins are expressed predominantly in axons and are brain-specific 
microtubule-associated proteins. The function of tau is presumably to stabilize the 
microtubule that serves as tracks for cytoplasmic transport (Tucker, 1990). 
Mutations in tau were found in various fronto-temporal degeneration (FTD) 
disorders (Heutink et al., 2000). Missense mutations in tau have been shown both to 
increase self-aggregation and to reduce microtubule binding (Rizzu et al., 2000; 
Arrasate et al, 1999; Perez et al., 2000). Other intronic mutations alter splicing and 
hence the ratio of isoforms with either three or four microtubule binding domains 
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(D'Souza et al, 1999; Grover et al., 1995). As there is competition for microtubule 
binding between the different isoforms (Lu and Kosik，2001). Both the intronic and 
exonic mutations have been shown to decrease binding of tau to microtubules. Hence, 
increases in free, unbound tau, also enchance the possibility of tau aggregation. 
1.3.2.2 Paired helical filaments (PHF) 
PHF are mainly composed of hyperphosphorylated tau protein. Tau protein 
isolated from normal adult brain contains 2-3 moles of phosphate per mole of tau 
protein whereas form AD brain, it contains 5-12 moles (Selden and Pollard, 1983). 
About half of the known phosphorylation sites in PHF are serine or threonine residues 
followed by a proline (reviewed by Goedert et al,, 1997). 
1.3.2.3 Tau protein kinase (TPK) 
Protein phosphorylation is one of the major mechanisms for the regulation 
of many biological functions. One of the key events in the formation of PHF-tau 
involves the hyperphosphorylation of normal adult brain tau, which renders the 
abnormal proteins incapable of binding to microtubules and a loss of tau-induced 
microtubule stabilization (Goedert et al., 1993; Bramblett et al., 1993). At present, it 
is not known which kinase involved in the initial stages or how such protein kinases 
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interact to bring about the final phosphorylation state of tau. TPKI and n were found 
as candidate enzymes responsible for hyperphosphorylation of tau to induce the 
formation of PHF. TPKI and TPKII were identified as glycogen synthase 
kinase(GSK)-3 and cyclin-dependent kinase 5 (CDK5). The phosphorylation sites 
on tau by TPKI and TPKII account for most, but not all of the major phosphorylation 
sites of fetal tau and PHF-tau (reviewed by Imahori and Uchida, 1997). 
1.3.2.3.1 Glycogen synthase kinase-3 (GSK-3) 
GSK-3 is a serine/threonine-specific kinase, which was initially found to be 
able to phosphorylate and thereby inactivate glycogen synthase (Embi et al., 1980; 
Hemmings et al., 1981; Hughes et al., 1993). It is identified as TPKI and is crucially 
involved in the hyper-phosphorylation of tau in AD (Lovestone and Reynolds, 1997). 
GSK-3, especially the P-isoform, is associated with the paired helical filaments (PHF) 
found in the AD brains (Shiruba et al., 1996; Yamaguchi et al., 1996; Pei et al., 1997). 
GSK-3(3 has been shown to phosphorylate tau in vitro on several serine and threonine 
residues known to be phosphorylated in PHF-tau (Lovestone et al, 1994; Mulct et al., 
1994; Anderton etal., 1995). 
1.3.2.3.2 Cyclin-dependent kinase 5 (CDK5) 
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CDK5 is a proline-directed kinase that phosphorylates serine and threonines 
immediately upstream of a proline residue. Like other CDKs, monomeric CDK5 
shows no enzymatic activity and requires association with a regulatory partner for 
activation. Two activators of CDKS, p35 and p39 have been identified (Lew et a/., 
1994; Tsai et al” 1994; Ishiguro et al, 1994). Deregulation of CDKS through the 
proteolytic cleavage of p35 to generate p25 is associated with Alzheimer's disease 
(reviewed by Dhavan and Tsai, 2001). In transfected cells and cultured neurons, 
p35-CDK poorly phosphorylates tau, whereas tau is potently phosphorylated by 
p25-CDK5 (Patrick et al., 1999). TPKII/p25-CDK5 was shown to be associated with 
neurofibrillary tangles in vivo (Pei et al., 1998), and phosphorylated tau on sites found 
in PHF-tau (Paudel et al., 1993). 
1.3.2.4 Tangle leads to dementia 
There were substantial attempts to ascertain which pathological lesion was 
responsible for the clinical features of AD that showed good correlation between 
cognitive state and the numbers of tangles (Nagy et al., 1995). The process of tangle 
formation starts with increased phosphorylation and then aggregation of tau in those 
areas known to be critical for memory (Braak et al, 1994; Braak and Braak, 1998). 
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Fig. 1-6 Summary of tau and tangle hypothesis. Tau binding to microtubules is 
disrupted by phosphorylation, directly by mutations that alter fiinction, and by 
mutations that alter isoform expression. Decreased tau binding to microtubules might 
result in increased free tau, which under the appropriate conditions, will 
self-aggregate to form insoluble paired helical filaments. Loss of tau binding is 
predicted to result in loss of microtubule function. The process of tau aggregation in 
the absence of mutations is not known but might result from increased 
phosphorylation, protease action or exposure to polyanions， such as 
glycosaminoglycans (Mudher and Lovestone, 1999). 
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1.4 Cross-talk between the two hypotheses 
There had been many arguments supporting each hypothesis as the sole 
cause of AD. However, recent researches have shown that both hypotheses may 
harmonize together. A transgenic mouse overexpressing both APP and mutant tau had 
more tangles than tau-mutant mice alone and tangles appear in areas of the brain that 
are unaffected in single mutant-tau transgenic mice (Levis et aL, 2001). In a parallel 
experiment another group showed that injection of amyloid into the cerebrum of 
mutant tau transgenic mice exacerbated tangle pathology in another brain region from 
where neurons project to the injection site (Gotz et aL, 2001) 
1.5 Detail description of y5 -secretase (BACE) 
1.5.1 Discovery of -secretase (BACE) 
In late 1999, P-secretase was identified as a novel membrane-bound 
protease of 501 amino acids in length belonging to the pepsin family of aspartyl 
protease. The enzyme has been named as P-site cleaving enzyme (BACE), Asp2 and 
memapsin 2 by four different groups (Hussain et al., 1999; Sinha et al., 1999; Vassar 
et al., 1999; Yan et al., 1999). The targeting of this protease for specific inhibitors of 
(3-amyloid production has opened a new therapeutic approach in treating Alzheimer's 
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disease. At the amino acid level, BACE shows less than 30% sequence identity with 
human pepsin family members, with most similarity to cathepsin E (30% identity, 
37% similarity). The homology to other pepsins is highest in the central portion of 
BACE, while the NHa- and COOH-termini are more divergent. The low sequence 
similarity of BACE to pepsins together with the putative transmembrane domain 
indicate that BACE may define a new subclass of membrane-bound aspartic 
proteases. 
It has previously been reported that BACE mRNA is expressed widely at 
low levels, at moderate levels in the brain and at higher levels in the pancreas (Vassar 
et al., 1999; Yan et al., 1999). However, P-secretase activity is low in pancreas and 
highest in brain (Sinha et aL, 1999). This discrepancy between mRNA and activity is 
probably due to a slice variant lacking two-thirds of exon 3 being the predominant 
BACE transcript in pancreas, resulting in a protein that is incompletely processed and 
retained in the endoplasmic reticulum (Bodendorf et al., 2001). In the brain, BACE 
mRNA is widely expressed only in neurons, with most pronounced expression in the 
cerebellum, cortex and hippocampus observed by in situ hybridization (Vassar et al, 
1999). BACE is co-localized with its substrate, APP, in the trans-Golgi network of 
cells (Hussain et a/.,1999; Vassar et al., 1999). 
1.5.2 Detailed structure of BACE 
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As commonly found in other aspartyl proteases, BACE was synthesised as 
zymogen with a pre- and pro-domain which are proteolytically cleaved by signal 
enzymes. The BACE protein has an NH2-terminal signal peptide of 21 amino acids 
followed by a proprotein domain spanning amino acid 22 to 45�The lumenal domain 
of the protein extends from residues 46 to 460，and is followed by one predicted 
transmembrane domain of 17 residues and a short cytosolic COOH-terminal tail of 24 
amino acids (Vassar et al., 1999). 
BACE contains two active site motifs at amino acids 93 to 96 and 289 to 
292 in the lumenal domain. Each motif contains the highly conserved signature 
sequence of aspartic proteases, dT/sGT/s, within which the aspartic acid residue is 
essential for catalytic activity (reviewed by Rawlings and Barrett, 1995). BACE also 
has four putative N-linked glycosylation sites and six lumenal cysteines, which would 
allow the formation of up to three intramolecular disulfide bonds. Thus, BACE is 
predicted to be a type I transmembrane protein with the active site on the lumenal side 
of the membrane, where it catalyses the cleavage of APP. A schematic presentation of 
human BACE is shown in Fig. 3-1 A. 
The pro-domains are commonly found in protease precursors where they 
have been shown to virtually abolish catalytic activity (Khan and James, 1998) and to 
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assist in protein folding (Baker et a/., 1993; Shi et al., 2001). The pro-domain is 
typically cleaved from the protease precursor to generate the mature active protease. 
Edman degradation of purified human brain BACE revealed a single N-terminal 
protein sequence that began at the protease domain (Sinha et al., 1999) (this species 
was designated as mature BACE). 
1.5.3 Comparsion of human and mouse BACE 
The mouse homolog of BACE was identified through a computer search of an 
Amgen expressed sequence tag database. The mouse BACE (GenBank Accession 
number AF190726) has 93% sequence identity with the cDNA of human BACE. Both 
the mouse cDNAs encode proteins of 501 amino acids that have 96% identity with the 
human BACE protein (Vassar et al., 1999). Fig. 3-IB shows the schematic diagram of 
mouse BACE structure. 
1.5.4 Comparsion of BACE-1 with BACE-2 
A close homologue was also identified and termed as BACE-2, Aspl, DRAP, 
or memapsin 1 (Hussain et al,, 1999; Acquati et al., 2000; Farzan et al., 2000; Lin et 
al., 2000). Both enzymes are type I membrane proteins sharing significant homology 
with other members of the aspartyl protease family (Sinha et al., 1999; Vassar et al., 
2 7 
1999; Yan et al., 1999; Lin et al., 2000). The role ofBACE-2 in the pathogenesis of 
Alzheimer's is presently unclear as BACE-2 is predominantly expressed in peripherial 
tissues. 
1.5.5 Properties of BACE 
According to the current hypothesis, BACE and APP are both membrane 
proteins present in human brain and are co-localized in the same neuronal cells 
(Vassar et al., 1999; Hussain et aL, 1999; Lin et al., 2000). BACE specifically cleaves 
the P-secretase site of APP in cells and preferentially cleaves the P-secretase site from 
the Swedish mutation over the wild-type APP (Vassar et al., 1999; Yan et al., 1999; 
ErmoliefF et al., 2000; Lin et al., 2000). The acidic pH optimum for BACE activity 
(ErmoliefF et al., 2000; Lin et al,, 2000) is consistent with the previous observations 
that p-secretase cleavage occurs in acidic vesicles (Knops et al., 1995). BACE is not 
inhibited by many protease inhibitors, such as leupeptin (serine/cysteine proteinase 
inhibitor), 3,4-DCIC (serine proteinase inhibitor), PMSF (serine/cysteine proteinase 
inhibitor) and the classical aspartyl protease inhibitor pepstatin (pepsin inhibitor) in 
vitro, though BACE is structurally related to the pepsin aspartic protease family 
(Vassar et al, 1999; Bennett et al., 2000; Mallender et aL, 2001). BACE may be a 
new class of protease because of its broad spectrum inhibitor insensitivity despite its 
sequence classification as an aspartyl protease (Yamazaki and Ihara, 1998; Vassar et 
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al., 1999). 
Swedish mutation is associated with family early onset of Alzheimer's 
disease (Mullan et a/., 1992; Cai et al., 1993). Overproduction of the 42-amino acid 
form of A ^42, has been suggested to be the cause of all known cases of 
familial early onset AD (Younkin, 1998). This is correlated with the results that 
BACE showed higher preference of cleavage towards Swedish mutation peptide than 
wild type peptide (Vassar et al,, 1999; Yan et al., 1999; Lin et a/., 2000) and much 
greater release of from cells stably transfected with Swedish mutation APP than 
those with wild type APP (Citron et al., 1992; Hussain et al., 1999; Vassar et al., 
1999). 
1.5.6 Expression of BACE in E. coli 
In this study, both the cDNAs for human and mouse BACE were cloned by 
reverse-transcription polymerase chain reaction (RT-PCR). The cDNAs of human and 
mouse BACE with the deletion of transmembrane region and pro-domain were also 
amplified by PCR approach and then sub cloned into prokaryotic expression vectors. 
The objective was to provide recombinant BACE expressed in E.coli. The human 
BACE cDNA with deletion of transmembrane and pre-region was named as 
prohBACE. The human BACE cDNA with deletion of transmembrane, pre- and 
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pro-region was named as nohBACE, where 'h' means human. Similarly, the mouse 
BACE cDNA with deletion of transmembrane, pre and pro region was named as 
nomBACE gene, where ‘m，means mouse. Fig 3-1A and 3-IB shows the schematic 
diagram of human and mouse BACE and their domain organisation. 
1.5.7 Expression of BACE in mammalian cells 
In this study, stably transfected cell lines over-expressed with human and 
mouse BACEs were developed. The reason for expression of protein in mammalian 
cells was to compare with those in E.coli. Although the expression of protein in E.coli, 
can allow us to obtain larger amount of protein in relatively short time, however, due 
to incorrect folding in inclusion body, most of proteins are inactive unless they refold 
correctly under special conditions. The expression of protein in mammalian cells, on 
the other hand, can allow us to obtain a more correctly refolding protein, and is more 
close to cells that produced in vivo. The stably transfected cell lines are also an 
excellent model system to investigate the intracellular trafficking and location of 
BACE in the cells. 
In this study, both the full coding sequences of mouse and human BACE 
were subcloned into mammalian expression vectors pCDNA3 and pCDNA4HisMax. 
These vectors were used to transfect Chinese hamster ovary (CHO) cells. 
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Fig. 3-1 Schematic representation of the protein structure of the human (A) and mouse 
(B) BACE precursor protein and its domain structure as deduced from its cDNA 
sequence. Full length BACE is composed of several domains that include the 
Pre(residues 1-21), Pro (residues 22-45), protease (residues 46-460), transmembrane 
(TM; residues 461-477) and cytosolic tail (residues 478-501) regions. The amino acid 
sequence of the putative pro-region is shown (Shi et al., 2001). 
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1.6 Objectives of the present study 
At the beginning of my thesis, much of work has already been done to 
investigate the protease that functions as p-secretase. However, not much progress has 
been made until four different research groups independently cloned the then elusive 
P-secretase by genetic screening, direct enzyme purification and sequencing 
approaches (Vassar et al., 1999; Yan et a/., 1999, Sinha et al., 1999; Hussain et al., 
1999). The fi -secretase was named as beta-site APP-cleaving enzyme (BACE) and 
membrane-bound aspartyl protease (Asp2). BACE possesses many of the features of 
-secretase. BACE can cleave full-length APP at Aspl of the A ^ sequence and 
also at Glull, which is an alternative cleavage site (Vassar et a/.，1999). The Swedish 
mutation, which is known to enhance /3 -secretase cleavage (Forman et al., 1997), also 
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promotes cleavage of APP at Aspl by BACE (Vassar et al, 1999). BACE is 
expressed coordinately with APP in many regions of the brain, particularly in neurons, 
and has a subcellular distribution similar to that of -secretase (Vassar et al., 1999). 
Cell biology studies suggest three potential sites of intracellular BACE activity: 
endosomal/lysosomal compartments, Golgi apparatus and endoplasmic 
reticulum/intermediate compartments in postmitotic neurons (Chyung et al., 1997). 
BACE has an acidic pH optimum(Vassar et al., 1999; Ermolieff et al., 2000). 
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After the elucidation of BACE, the BACE has become a potential drug 
target for AD drug treatment. My study is thus aimed at setting up reliable assay 
systems for BACE. This involved the cloning of mouse and human BACE by PCR 
and subcloning of these cDNAs into appropriate expression vectors. The expression 
of BACE protein from E.coli. and mammalian cells. The stable cell lines 
overexpressed with mouse BACE and human BACE were established. Enzymatic 
assays were established by the synthesis of model peptide substrates for proteolyic 
cleavage by recombinant BACE by analytical reverse-phase high performance liquid 
chromatography (RP-HPLC). The activity of recombinant enzyme was also measured 
by a fluorometric assay with a custom-made fluorogenic substrate.. 
Besides, the intracellular location of BACE was studied by 
immunofluorescence. Polyclonal antibody, hBACE485, purchased from ALEXIS was 
used as primary antibody. Immunohistochemistry was conducted to the mammalian 
cell line stably expressing BACE using the polyclonal antibody to determine 
intracellular location of BACE 
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Chapter 2 Materials and Methods 
Chapter 2 
Materials and Methods 
2.1 Recombinant DNA techniques 
2.1.1 Amplification of genes by PCR techniques 
Polymerase chain reaction (PCR) was performed with 5 fi g/ml template in 
IjlX of 10/zM forward primer, 10//M backward primer, 0.2mM dNTPs, 1.5 mM 
MgCh, 1 X PCR buffer (20 mM Tris-HCl, pH 8.4 and 50 mM KCl), 5% DMSO and 
Tag DNA polymerase (Invitrogen) of 2.5 U. Thirty-five cycles were done at the 
following temperatures: 94°C for 1 minute, 58 for 30 seconds, and 72 for 2.5 
minutes and 7 minutes final extension at 72 
2.1.2 Agarose gel electrophoresis 
DNA was usually separated by 1 % (w/v) TAB agarose gel. Agarose was 
weighed at 1% (w/v) according to the gel volume. It was then dissolved by heating in 
IxTAE buffer. The gel solution was cooled to luke-warm before ethidium bromide 
(EB) (at a final concentration of 0.5 |ig/ml) was added. The gel solution was poured to 
the gel tray with comb inserted near the top margin. After 30 minutes hardened gel 
was formed. DNA sample was mixed with 6x gel loading buffer to obtain Ix final 
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concentration. After the gel was formed, it was put into the gel-tank pre-filled with 
TAE buffer at the level just covering the gel. Then the sample was loaded into the 
sample slots of the gel. The setup was operated at a rate of 8V/cm until the 
bromophenol blue dye was migrated to the desired distance. The separated DNA 
band(s) in the gel could be examined under UV illumination. The gel photo was taken 
by Polaroid MP-4 instant camera on Polaroid film. 
2.1.3 Extraction of DNA from agarose gel 
The extraction was done according to QIAquick Gel Extraction Kit (Qiagen, 
USA). The DNA fragment was excised from agarose gel with a clean, sharp scalpel. 
After weighing the gel slice in a colorless tube. 3 volumes of Buffer QG was added to 
1 volume of gel. The gel buffer solution was incubated at 50 for 10 minutes. To 
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help dissolve the gel, the solution was vigorously mixed by vortexing the tube every 2 
minutes during the incubation. After the gel slice was dissolved completely that that 
the color of the mixture became yellow, the gel solution was loaded on a QIAquick 
spin column in a provided 2 ml collection tube. The column was then centrifuged at 
10,000 X g for 1 minute to remove unbounded materials. The column was then 
washed by adding 0.75 ml of buffer PE to the column followed by centrifugation for 1 
minute. The flow through was discarded and the column was washed once more with 
0.75 ml buffer PE. An amount of 30 (il elution buffer was added and after incubation 
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for 1 minute, the bound DNA was eluted from the column by centrifugation at 10,000 
X g for 1 minute to a 1.5 ml microfuge tube. 
2.1A Digestion of various vectors and insert 
Restriction digestion of DNA was carried out in a reaction volume of 20 |il 
for small amount of DNA (0.5 to 5 [ig). The reaction mixture consisted of DNA 
sample, appropriate restriction digestion buffer, double distilled water, bovine serum 
albumin (BSA) (optional) and restriction enzyme(s). The selection of restriction 
digestion buffer was based on the type of restriction enzyme in use and was according 
to the manufacturer's suggestion. The amount of restriction enzyme added was 
usually in activity units 5-fold or higher of the DNA amount in microgram. The 
reaction was incubated at the optimal temperature of the enzyme in use for 2 hours or 
longer. After digestion, the products were analyzed by agarose gel electrophoresis. 
2.1.5 Ligation of DNA fragments 
The following procedure describes the general condition for ligation of 
foreign DNA to a linearized vector. 100 ng of the vector and 3-fold molar amount of 
foreign DNA were mixed together. Then lOx ligation buffer was added to the reaction 
mixture to a final concentration of Ix. 1 unit of T4 DNA ligase (Promega) was added 
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and the mixture was incubated at 16°C for 16 hours. 
2.1.6 Preparation of Escherichia coli competent cells 
An appropriate strain of Escherichia coli (E.coli) was streaked directly from 
a — 70�C frozen stock onto the surface of a LB agar plate and incubated for 16 hours at 
37°C. A single bacterial colony was picked by a sterile toothpick and inoculated into 
50 ml LB medium. Bacteria cultures were allowed to grow overnight at 37°C with 
constant shaking at 250 rpm. An aliquot of 4-ml culture was inoculated into 400 ml 
LB medium in a sterile 2-liter flask. The cells were allowed to grow at 3TC until 
ODeoo reaching 0.4, which represents a cell density of 4-7x10^ cells/ml. Then the 
culture was chilled in ice for 15 minutes. The cells were harvested by centrifugation at 
1600 X g for 10 minutes at 4°C. The supernatant was discarded and the pellet was 
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resuspended in 10 ml of ice-cold CaCb solution. The cells were collected by 
centrifugation at llOOxg at for 5 minutes. The supernatant was discarded and the 
pellet was resuspended in 10 ml ice-cold CaCl� solution and was incubated on ice for 
30 minutes. The cells were then collected by centrifugation at llOOxg at 4 for 5 
minutes. The supernatant was discarded and the pellet was resuspended in 2 ml 
ice-cold CaCl2 solution. The cells were dispensed in aliquots of 250 [il into 1.5 ml 
tubes and kept frozen immediately at -70�C until use. 
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2.1.7 Bacterial transformation 
A frozen tube of competent cells was thawed in an ice bath. An appropriate 
amount of plasmid (1-10 ng) or ligation mixture was added to the competent cells, 
followed by mixing moderately and kept chilling on ice for 30 minutes. The mixture 
tube was then heat-shocked at 42°C by incubating the tube in water bath for 90 
seconds. Then the tube was again chilled in ice rapidly for 10 minutes. An amount of 
500 |il of 37°C pre-warmed LB medium was added to the tube in sterile condition. 
The tube was incubated in ？>TC for 45 minutes and appropriate fraction of the cells 
was spread evenly onto a LB plate with antibiotic according to the resistance 
conferred by the transformed plasmid. The plate was placed in an inverted position in 
an incubator at 37°C for 16 hours to obtain plasmid-containing colonies. 
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2.1.8 Minipreparation of plasmid DNA 
A single bacterial colony was inoculated into 2.0 ml LB medium containing 
the containing the appropriate antibiotic in a capped sterile tube. The culture was 
incubated overnight at 37°C with vigorous shaking. The bacterial cells were collected 
by centrifugation at 12,000 x g for one minute at room temperature in a 
microcentrifuge. The bacterial pellet was suspended in 200 jil solution I. Then 100 |il 
solution II was added and the mixture was kept on ice for 5 minutes. After 150 jil 
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solution III was added, the mixture was centrifuged at 12,000xg for 10 minutes at 
The supernatant was transferred to fresh tube containing 800 95% ethanol and was 
allowed to sit at room temperature for 2 minutes. Plasmid DNA and RNA were 
collected by centrifugation at 12,000g for 1 minute. After removing the supernatant, 
the pellet was washed with 1 ml of 70% ethanol and dried under vacuum. The pellet 
was resuspended in 30 TE buffer and RNase (at final concentration of 100 jig/ml) 
was added to digest the RNA remained in the solution. 
2.1.9 Large scale preparation of plasmids 
A single colony of bacteria containing cloning plasmid was inoculated into 
2 ml LB medium containing 100 fxg/ml ampicillin or appropriate antibiotic. After an 
overnight incubation at 37^C with constant shaking, a 1-ml aliqot of the bacterial 
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culture was inoculated to 100ml LB medium containing 100 [ig/ml ampicillin in a 
500-ml flask and incubated at 37^C with constant shaking until the culture reached 
saturated condition (OD6oo=4). The cells were collected by centrifuging for 12 
minutes at 6000 x g at and the resulting cell pellet was resuspended in 4 ml 
solution I, followed by an addition of 8ml solution II to the mixture. After an 
incubation on ice for 10 minutes. 6 ml solution IE was added to the mixture and 
allowed to stand on ice for 15 minutes. The mixture was then centrifuged for 20,000g 
for 10 minutes at and the resulting supernatant was collected. A 0.6 volume of 
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isopropanol was added to the supernatant and incubated room temperature for 20 
minutes. The solution was centrifuged at 20,000g for 15 minutes. The resulting DNA 
pellet was then washed with 75% ethanol and dried under vacuum. The DNA pellet 
was resuspended in 1 ml TE buffer and stand at overnight. The insoluble material 
was removed by centrifugation at 20,000 x g for 5 minutes. The clear supernatant was 
transferred to a clean tube. The plasmid DNA was further extracted with 1 volume of 
buffered phenol, then with 1 volume of chloroform/isoamyl alcohol (24:lv/v). After 
transferring the aqueous phase to a clean tube, an amount of 1/4 volume 10 M 
ammonium acetate (2M final concentration) and 2 volumes of 100% ethanol were 
added and mixed thoroughly. The plasmid DNA was recovered by centrifuging for 10 
minutes at 10,000 x g at 4°C. After washing the pellet with 70% ethanol and dried 
briefly under vacuum. The DNA pellet was resuspended in 2 ml TE buffer followed 
by an addition of 0.8 ml polyethylene glycol (PEG) solution. After an incubation for 1 
to 15 hours at 0 the plasmid DNA was recovered by centrifuging for 20 minutes at 
10,000g X g at The purified plasmid DNA was finally re-dissolved in 1 ml TE 
buffer. If necessary, the plasmid DNA was ethanol precipitated by acidifying the 
solution with 3M sodium acetate, pH 5.5 followed by an addition of 2 volumes of 
ethanol. 
2.1.10 Strain storage and revival 
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After successful transformation, the bacteria strain was kept for long-term 
storage by making glycerol stock for future use. Briefly, a single bacterial colony was 
picked on sterile toothpick and inoculated by dipping the toothpick in 2 ml LB 
medium in a sterile Falcon tube. After growing the bacteria culture at 37°C with 
constant shaking at 250 rpm until the optical density of the bacteria culture reached 
ODeoo of approximately 0.6. An amount of 1-ml bacteria culture were taken and 
mixed with 1ml of 30% glycerol and stored at -70°C. 
Upon retrieval of bacterial clone, the cell stock in frozen glycerol-LB 
culture was picked by scraping with a flame-sterile, cooled inoculating loop and 
inoculated in LB medium with or without antibiotic according the properties of the 
bacteria. 
2.1.11 Plasmid DNA purification by High Pure plasmid isolation kit 
The purification of plasmid DNA was done by high pure plasmid isolation 
kit (Roche). A single bacterial colony was grown in 2 ml LB medium containing 
appropriate antibiotics until the optical density of the culture reached ODeoo at 2.0. 
The bacterial cells were then recovered by centrifugation at 9,000 rpm for 30 seconds. 
After carefully removing the supernatant, the pellet was resuspended in 250 |il 
Suspension Buffer and RNase and mixed well. The solution was mixed gently with 
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250 |J1 Lysis Buffer by inverting the tube 3 to 6 times and then incubated at room 
temperature for 5 minutes. 350 |il of Binding Buffer was added and mixed gently by 
inverting the tube 3 to 6 times and incubated on ice for 5 minutes. The solution was 
then centrifuged on a microcentrifuge at 14,000 rpm for 10 minutes and the 
supernatant was transferred to the upper reservoir of each of the High pure filter tube 
(Roche) connected to an collection tube. The tube was centrifuged at 14,000 rpm for 
60 seconds and the flow-through solution was discarded. After connecting the filter 
tube to the same collection tube, an amount of 700 |il Wash Buffer II was added to the 
upper reservoir and centrifuged at 14,000 rpm for 60 seconds. The flow-through 
solution was discarded and another 700 |xl Wash buffer was added to the filter tube 
and the washing procedure was repeated two times. After the washing steps, the filter 
tube was connected into a clean 1.5 ml microcentrifuge tube. An amount of 100 |il 
Elution Buffer was added to the upper reservoir of the filter tube and the bounded 
DNA was eluted from the filter tube by centrifugation at 14,000 rpm for 30 seconds. 
2.1.12 DNA sequencing 
The cloned plasmid DNA was sequenced to confirm identity of the cDNAs 
and to ensure proper open reading frame of the cDNAs was obtained. Sequencing 
reactions were boiled at 95°C for 5 minutes and cycled for 40 times at 94°C for 36 
seconds, 50°C for 36 seconds, ITC for 2 minutes and a 10 minutes final extension at 
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72°C using T7 or T3 universal sequencing primers. The sequencing products were run 
and analyzed in LI-COR 4200 DNA sequencer or MegaBACE 1000 system. 
2.1.13 Quantitation of DNA by spectrophotometric method 
The DNA concentration was calculated by spectrophotometric method 
based on the following relationship: OD260 nm =1 is equivalent to to 50 ^g/ml 
double-stranded DNA. A small volume (1-10 [i\) of DNA sample was diluted in 500 
[i\ TE buffer and the diluted DNA sample was transferred to a quartz curvette. The 
absorbance was measured at OD260 nm so that the reading was in the range 0.1-1 by 
adjusting the dilution of sample. TE was used as blank to correct for background 
absorbance. The purity of DNA sample could be determined by the ratio of its 
absorbance at OD260 nm and OD280 nm- If the ratio of the former data to the latter data is 
1.8 or above, the DNA sample was considered to be pure. 
2.2 Prokaryotic protein expression 
2.2.1 Selection of appropriate clones for recombinant protein expression using 
conventional method 
The bacterial colonies harboring expression vectors suitable for 
recombinant protein expression (i.e. BL21(DE3)LysS strain of E. coif) were screened 
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for proper induction of recombinant protein expression. It was done by streaking the 
frozen bacterial stocks on LB agar plates with appropriate antibiotics. After an 
overnight incubation at 37°C, selected bacterial colonies were grown in 2 ml LB 
medium with 100 |Lig/ml ampicillin and 37 \ig/m\ chloramphenical at 37°C overnight 
with orbital shaking at 240 rpm. 10 |li1 of cell culture was added to 2 ml freshly 
prepared LB medium with 100 ^g/ml ampicillin and 37 |Lig/ml chloramphenical. Cells 
were collected when cell density reached ODeoo of 0.2-0.6. Afterwards, an aliquot of 
0.5 ml of bacterial culture was taken and kept for SDS-PAGE analysis and an aliquot 
of 0.5 ml for preparing 15 % glycerol stock. The remaining bacterial culture was used 
for induction of expression of recombinant protein by 0.4 mM IPTG and the culture 
was allowed to grow for 3 hours at 37°C with orbital shaking at 240 rpm for optimal 
recombinant protein expression. 
2.2.2 Selection of appropriate clones for recombinant protein expression using 
modified method 
Modified expression method was performed according to (Studier et al., 
1990). The bacterial colonies harboring expression vectors suitable for recombinant 
protein expression were screened for proper induction of recombinant protein 
expression. It was done by streaking the frozen bacterial stocks on LB agar plates with 
appropriate antibiotics. After an overnight incubation at 37°C, selected bacterial 
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colonies were grown in 2 ml LB medium with 100 |Lig/ml ampicillin and 37 jiig/ml 
chloramphenical at 37°C until ODeoo reach 0.2-0.6 with orbital shaking at 240 rpm. 
The cells were pelleted at 10,000 x g for 2 minutes. After removing the supernatant, 
the cells were resuspended in 2 ml fresh LB. An aliquot of 100 \i\ culture was added 
to 8 ml LB containing 100 |Lig/ml ampicillin and 37 |Lig/ml chloramphenical. Bacterial 
culture was allowed to grow until ODeoo reach 0.2-0.6 with orbital shaking at 240 rpm. 
The cells were collected at 6,000 x g for 6 minutes and resuspended in 2 ml LB 
containing 100 \ig/m\ ampicillin and 37 \ig/m\ chloramphenical. Afterwards, an 
aliquot of 0.5 ml of bacterial culture was taken and kept for SDS-PAGE analysis and 
an aliquot of 0.5 ml for preparing 15 % glycerol stock. The remaining bacterial 
culture was used for induction of expression of recombinant protein by 0.4 mM IPTG 
and the culture was allowed to grow for 3 hours at 37°C with orbital shaking at 240 
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rpm for optimal recombinant protein expression. 
2.2.3 Large -scale expression of recombinant human BACE protein using 
modified method 
The clone that was demonstrated to express human BACE protein as 
indicated by SDS-PAGE analysis was used for a large-scale culture. The streaking of 
the 15% glycerol bacterial stock of that clone was added into 2 ml LB broth with 100 
|Lig/ml ampicillin and 37 |Lig/ml chloramphenical, and grown in 100 ml LB broth with 
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100 \ig/m\ ampicillin and 37 |ig/ml chloramphenical at 37�C until ODeoo reach 0.2-0.6 
with orbital shaking at 240 rpm. The cells were centrifuged at 10,000 x g for 2 
minutes. After removing the supernatant, the cells were resuspended in 100 ml LB. 
An aliquot of 5 ml culture was added to 400 ml LB containing 100 jiig/ml ampicillin 
and 37 \ig/m\ chloramphenical. Bacterial culture was allowed to grow until ODeoo 
reach 0.2-0.6 with orbital shaking at 240 rpm. The cells were collected at 6,000 x g 
for 6 minutes and resuspended in 100 ml LB containing 100 jug/ml ampicillin and 37 
|ig/ml chloramphenical. An aliquot of 1 ml of bacterial culture was taken and kept for 
SDS-PAGE analysis. The induction of expression of recombinant protein was then 
initiated by the addition of 0.4 mM IPTG into the remaining bacterial culture and the 
culture was allowed to grow for 3 hours at with orbital shaking at 240 rpm. 
2.2.4 Preparation of inclusion body from the bacterial expression culture 
After induction of bacterial cells with IPTG, the cells were centrifuged at 
5,000 X g for 5 minutes. After decanting the LB broth, the pellet was dried as much as 
possible. The cells were dispersed by the addition of 40 ml binding buffer, followed 
by a brief sonication on ice. The cell solution was centrifuged at 16,000g for 15 
minutes to collect inclusion body. The pellet, which consisted of inclusion body, was 
resuspended in 20 ml binding buffer and then centrifuged at 16,000 x g for 15 minutes. 
After removing the supernatant, the pellet was resuspended in 20 ml buffer B with 8 
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M urea or in 2 ml buffer D with 6 M guanidine hydrochloride and incubated at room 
temperature for 1 hour to dissolve protein completely. Insoluble debris was removed 
by centrifugation at 16,000 x g for 30 minutes. 
2.2.5 Refolding of human BACE 
The protein was renatured by rapid dilution the protein solution in binding 
buffer B or buffer D to yield a final concentration of 0.8 M urea or 0.1 M guanidine 
HCl and incubated at room temperature for 2 and 6 hours respectively. The solution 
was then centrifuged at 10,000 x g for 20 minutes. The recombinant human BACE 
solution was concentrated by Centriprep 30 (Centricon) and stored in aliquots 
at -80°C. 
2.2.6 Purification of recombinant human BACE by immobilized metal ion 
affinity chromatography (IMAC) 
As the recombinant protein contained poly histidine residues at the 
N-terminus as a fusion tag, the protein can easily be purified by immobilized metal 
ion affinity chromatography (IMAC). The Chelating Sepharose Fast Flow (Pharmacia 
Biotech) consists of iminodiacetic acid groups coupled to Sepharose Fast Flow by 
stable ether linkages via a 7-atom spacer. The gel was washed with 3 columns of 
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double distilled water. Then, it is charged with nickel, Ni^ "^  ions by adding one column 
of 0.1 M NiS04. After washing the column with 2 columns of double distilled water 
and was equilibrated with 2 columns of buffer B with 0.8 M urea or buffer D with 0.1 
M guanidine HCl. The human BACE solution in buffer B with 0.8 M urea or buffer D 
with 0.1 M guanidine HCl was then applied to the column. Unbounded proteins were 
washed from the column by the addition of 2 column-volumes of buffer B with 0.8 M 
urea or buffer D with 0.1 M guanidine HCl containing 50 mM imidazole. The 
histidine-tagged recombinant protein was finally eluted by eluting the column with 1 
column-volume of buffer B with 0.8 M urea or buffer D with 0.1 M guanidine HCl 
with 200 mM imidazole. 
2.2.7 Protein concentration determination 
The protein concentration was determined by Bradford method (1976) 
(Bradford, 1976) and bovine serum albumin (BSA) was used as protein standard. 
2.2.8 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
The Mini-PROTEAN II electrophoresis cell (Bio-Rad) was used for 
SDS-PAGE. The gel-mould was assembled according to the manufacturer's 
instruction. Before casting the gel, small amount of distilled water was added to fill up 
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the gel-mould to check if leaking occurred. After draining the last bit of water by 
inserting filter paper strip between the two glass plates, 5 ml of 12% separating gel 
solution was then mixed according to section 2.7.4. The solution was pipetted into the 
gel-mould to two-third of total gel volume for preparation of the running gel. After 
the gel solution was pipetted to the gel gap at one side, a thin layer (approximately 1 
cm) of isopropanol was then added on the top of the solution surface to remove air 
bubbles and to keep the solution away from air. The gel was allowed to polymerize 
for more than 30 minutes. After polymerization, isopropanol was removed from the 
gel top. The stacking-gel mix was prepared according to section 2.7.4, and was 
pipetted on top of the running gel. A sample comb for sample slots was inserted into 
the stacking-gel layer immediately. The gel was ready to use after 15 minutes. The gel 
set up was assembled in the Bio-Rad gel-tank. Freshly prepared SDS-PAGE running 
buffer was poured to the cavity formed by electrode-unit and to the surrounding space. 
Protein samples were mixed with SDS sample loading buffer and boiled at 100°C for 
10 minutes. An amount of 40 |il of each denatured sample was loaded into the sample 
slot. The system was operated at a constant voltage of 120 V for 2 hours or until the 
blue front-dye just reaching the gel-end. 
Proteins on the gel was stained by immersing the gel in a staining solution. 
Staining could be done faster by staining at 42°C for 30 minutes. Excess stain was 
removed by gentle agitation in a destaining solution. 
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2.2.9 Western blotting 
After running SDS-PAGE as described previously, the gel used in Western 
blotting was immersed in transfer buffer for 30 minutes and transferred with a Mini 
Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) onto a PVDF membrane 
(Millipore) at 15 V for 1 hour. Non-specific binding sites of the PVDF membrane 
with bound protein was blocked with immunoblotting buffer for 45 minutes at room 
temperature. The membrane was probed with suitable antibodies (1:5000) in 
immunoblotting buffer and incubated at 4°C overnight. Alkaline phosphatase (AP) 
labeled goat anti-rabbit IgG antibodies (ZYMED) was used as the secondary 
antibodies (1:2500) and the membrane was incubated at room temperature for 1 hour 
with secondary antibodies. After washing with immunoblotting buffer, followed by 
buffer 3, signal was detected by incubating with 5-Bromo-4-Chloro-3-Indolyl 
phosphate (BCIP) and nitroblue tetrazolium (NET) in buffer 3 (at a final 
concentration of 0.01% and 0.02% respectively). The reaction was stopped until 
signal was detected by washing with distilled water. 
2.2.10 Plasmid stability test 
Plasmid stability test was performed according to (Studier et al., 1990) to 
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determine the fraction of cells that carry the target plasmid. The test was done as 
follows. Just before induction in section 2.2.1, when the bacterial culture had reached 
OD6OO=0.2-0.6, the culture were diluted into 10^  fold and spread on LB plates with 
IPTG and with antibiotics and IPTG. The culture was diluted into 2x10^ fold and 
spread on LB plates only and LB plates with antibiotics. The cells were allowed to 
grow overnight at 37�C. For stable plasmids, almost all the cells will form colonies 
both on LB plates only and on LB plates containing antibiotics, less than 2% of cells 
will grow on LB plates containing IPTG, and less than 0.01% of cells will grow on 
LB plates containing antibiotics and IPTG. 
2.3 Mammalian Cell Expression 
2.3.1 Transient transfection 
Chinese Hamster Ovary (CHO) cells were transfected with various plasmid 
constructs using Lipofectamine Plus Reagent (Life Technologies, Inc.). The CHO 
cells at the density of 1 x 10^  cells were grown on 35 mm dishes, until the cells were 
60-80% confluent. An amount (1 (ig) of purified mammalian expression plasmid 
DNA and 6 i^l of the Plus reagent (BRL) were added to 100 …DMEM medium 
lacking serum and antibiotics and incubated for 15 minutes at room temperature. An 
amount of 4 of lipofectamine reagent was added to 100 [il DMEM medium lacking 
serum and antibiotics to another tube and incubated for 15 minutes at room 
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temperature. The two solutions were mixed and incubated for another 15 minutes at 
room temperature. The cells were washed in PBS twice and then 1 ml of DMEM 
medium lacking serum and antibiotics was added to the cells. The DNA-lipofectamine 
plus mixture was added directly to the cells and incubated for 4 hours at 37�C. After 4 
hours incubation, the cells were rinsed in PBS and fresh DMEM medium 
supplemented with 10% FBS and 0.1 mM non essential amino acid (NEAA) was 
added followed by incubation for another 24 hours before harvesting the cells. 
2.3.2 Measuring transfection efficiency 
Cells transfected with plasmid containing lacZ gene were collected. The 
cells were washed twice with PBS. PBS was removed and the cells were fixed with 
0.2% glutaraldehyde in PBS for 5 minutes at room temperature. The cells were 
washed with PBS for 3 times. PBS was removed and the cells were stained with X-gal 
solution and incubated in humidified incubator of 37°C until signals had been 
detected. 
2.3.3 Stable transfection 
Various mammalian expression plasmid constructs were transfected into 
CHO cells as described in section 2.3.1. Transfected cells were grown in a 25 cm^ 
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culture flask for 24 hours. The culture medium was then replaced by fresh complete 
medium containing of 1 mg/ml of Geneticin® (G418 sulfate) (Gibco, BRL) for the 
cultures were kept for 3 weeks with subculturing of cells when necessary. The stably 
transfected cells were maintained in complete medium containing of 1.2 mg/ml 
G418 . 
2.3.4 Preparation of membrane extracts from CHO cells 
After the culturing medium was removed, and the CHO cells were washed 
with sterile PBS twice. The cells were then lysed by incubation with lysis buffer for 
30 minutes at 4°C. Cells were removed by centrifugation of 500 x g for 5 minutes. 
The supernatant was collected and centrifiiged at 26,000 rpm for 10 minutes in an 
ultracentrifuge (Beckman). The pellet was dissolved in assay buffer. 
2.4 HPLC analysis 
2.4.1 Preparation of samples 
The proteolytic activity of enzymes was analyzed by high performance 
liquid chromatography (HPLC). Two synthetic peptide substrates and one product 
peptide were synthesized in-house and used for the present study, which were shown 
in section 2.7.9. The amount of samples added were adjusted to 2 |Lig. The samples 
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were mixed according to section 2.7.9. and incubated for 2 hours at 37°C. The 
reaction was stopped by boiling and stored at -2(fC. The supernatant were collected 
by centrifuging at 10，000 x g for 5 minutes and analyzed by HPLC. 
2.4.2 Reverse phase HPLC 
Samples were analyzed by reverse phase HPLC separation on a Cig 
Protein/peptide reverse phase column (Vydac Ci8 218TP) using Waters HPLC system. 
The Vydac Cig reverse phase was first pre-equilibrated with buffer A at a flow rate 0.1 
ml/min. An amount of 50 of sample mix, as shown in section 2.7.9, was loaded into 
the HPLC. The eluate was monitored at UV 214 nm at a flow rate of 1 ml/min. The 
column was eluted with a gradient according to the following table. 
Table 1 Flow rate and different composition of buffer used in HPLC assay 
Time (minutes) Flow rate % of Buffer % of Buffer 
(ml/min) A B 
- 0 1.00 100 — 0 
“ 2 1 . 0 0 — 1 0 0 — 0 — 
32 1.00 0 100 
- 40 1.00 一 0 — 100 — 
- 45 1.00 — 100 — 0 — 
- 50 1.00 一 100 — 0 
- 51 0.10 I 100 I 0 — 
2.5 Fluorometric assay 
The BACE activity was also monitored by a fluorometric assay based on the 
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principle of fluorescence resonance energy transfer (FRET). Two fluorogenic 
substrates, FS-1 and FS-2 were shown in section 2.7.10. 2 |Lig of samples were added 
in each assay. The reaction mixture was prepared as described in section 2.7.10 and 
the enzyme activity was monitored by the release of quenched fluorescence. The 
mixture was incubated at 37°C for the fluorescence intensity was measured in a 
spectrofluorometer (SpectraMax Gemini) with an excitation wavelength of 350 nm 
and an emission wavelength of 490 nm at each hour interval. 
2.6 Immunohistochemistry 
The specimen were fixed in 4% paraformaldehyde solution at room 
temperature for 20 minutes, and further fixed with 100% methanol at room 
temperature for 5 minutes. The specimen were blocked with 2% normal goat serum in 
PBS and incubated at 37°C for 1 hour. It was then labeled by incubating for 3 hours 
with the hBACE485 antibody (1:50) in 2% normal goat serum in PBS, was then 
incubated at room temperature for 1 hour with fluorescein isothiocyanate 
(FITC)-conjugated goat anti-rabbit IgG (1:100) in PBS. The immunolabeled section 
was viewed in a Zeiss Axiophot microscope equipped with epifluorescence optics or 
examined in a Leica laser confocal microscope. 
2.7 Reagents and buffers 
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2.7.1 Medium for bacterial culture 
Luria-Bertani (LB) medium 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10g 
The solution was made up to IL with double distilled water and autoclaved at 121°C 
for 20 minutes 
LB agar plate 
The powder mixture in preparing LB medium was supplemented with 1.5% (w/v) 
bactoagar. 20 ml solution was poured to a 100 mm plate and cooled at room 
temperature until it was hardened. The plates were inverted and stored at 
LB agar plate with antibiotics 
The procedures were the same as preparing LB agar plate except ampicillin (at a final 
concentration of 100 |ig/ml) and/or chloramphenicol (at a final concentration of 37 
[xg/ml) was supplemented to the luke-hot LB agar solution before pouring onto plates. 










Potassium acetate(pH4.8) 250.6 g/1 
TE buffer 
Tris-Cl, pH7.4 10 mM 
EDTA, pH 8.0 ImM 
PEG solution 
PEG 8000 13% 
Desired volume was made by filling with 1.6 M NaCl. 
2.7.3 Buffers for agarose gel electrophoresis 
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TAB (Tris-acetate), Ix 
Tris-base 4.84 g/1 
Na2EDTA 0.34 g/1 
Acetic acid 20 mM 
6x agarose gel loading buffer 
Sucrose 40% (w/v) 
Bromophenol blue 0.25% (w/v) 
2.7.4 Buffers for SDS-PAGE 
30% Acrylamide mix 
Acrylamide 29 g/100ml 
N, N’ -Methylenebisacrylamide 1 g/100ml 
The solution was dissolved by warming at 37 filtered sterile and stored in darkness 
at 40c. 
12% separating gel solution 
ddHsO 3.3 ml 
30% acrylamide solution 4 ml 
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1.5 M Tris-HCL, pH 8.8 2.5 ml 
10% SDS 100 i^l 
10% w/v ammonium persulfate (APS) 100 fil 
TEMED 4 III 
5% stacking gel solution 
ddHaO 3.4 ml 
30% acrylamide solution 0.83 ml 
1.0 M Tris-HCl (pH 6.8) 0.63 ml 
10% SDS 50 
10% APS 50 III 
TEMED 5 ^ il 
SDS sample loading buffer 6x 
Tris-HCl (IM, pH 6.8) 3.5 ml 
SDS 1 g 
DTT 0.93 g 
Bromophenol blue 1.2 mg 
Glycerol (99%) 3 ml 
The solution was made up to 10 ml by ddHbO and stored as 0.5 ml aliquots at —70�C. 
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Running buffer 
Tris-base 3.02 g/1 
Glycine 18.8 g/1 
10% SDS 10 ml/1 
2.7.5 Buffer for purification of protein 
Binding buffer 1 x 
imidazole 5 mM 
NaCl 0.5 M 
Tris-HCl 20 mM 
The pH was adjusted to 7.8. 
Buffer B 
Tris-HCL (pH7.5) lOmM 
dithiothreitol, DTT 10 mM 
Buffer D 
NaCl 125 mM 
Tris-HCl 20mM 
The pH was adjusted to 7.2. 
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2.7.6 Buffer for Western Blotting 
Transfer buffer 
Tris-HCl 25mM 
Glycine 192 mM 
Methanol 10% (v/v) 
Immunoblotting buffer 
Skimmed dry milk 5% 
NaNa 0.02% 
Tris-HCl 50 mM 
CaCl2 2 mM 
NaCl 80 mM 
The pH was adjusted to 7.4 and prepared freshly. 
Buffer 3 




Antibodies against BACE 
hBACE122 (ALEXIS) 
A rabbit polyclonal antibody raised against a 10-residue synthetic peptide 
(RDLRKGVYVP) corresponding to the human BACE gene (residues 122-131). 
hBACE485 (ALEXIS) 
A rabbit polyclonal antibody raised against a 17-residue synthetic peptide 
(C485LRQQHDDFADDISLLK501) corresponding to the human BACE gene 
C-terminal region (residues 485-501). 
2.7.7 Culturing medium of CHO cells 
DMEM medium 
DMEM powder 1 Og 
NaHCOs 3.7g 
The solution was made up to 10 ml by ddHiO, pH was adjusted to 7.4 by IM HCl or 
NAOH, and solution was filtered and stored at 4°C. 
DMEM with 0.1 mM NEAA 
10 mM NEAA solution was added to DMEM medium (final concentration of 0.1 
mM) 
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DMEM medium with 0.1 mM NEAA and ampicillin 
10,000 |ag/ml penicillin-streptomycin was added to DMEM medium with 0.1 
mM NEAA (final concentration of 100 jig/ml). 
Lysis buffer 
Tris-HCl, pH 7.4 50 mM 
Triton X-100 1% 
PMSF 1 mM 
Leupeptin 0.5 (j,g/ml 
Assay buffer 
Sodium acetate, pH4.8 20 mM 
Trition X-100 0.06% 
EDTA, pH8.15 5 mM 
PMSF 1 mM 
Leupeptin 0.5 jig/ml 
2.7.8 Solutions for estimating transfection efficiency 
X-gal solution 
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X-gal (50mg/ml in dimethylformamide) 40 
0.5MK3Fe(CN)6 20 ^1 
0.5MK4Fe(CN)6 20 ^1 
lMMgCl2 4^1 
IxPBS 1.916 ml 
X-gal (50mg/ml in dimethylformamide) was added to the mixture just before use. 
2.7.9 Reagents for HPLC 
Substrate 
BACE synthetic peptide substrate, EVKMDAEFR 
(Acetyl-Glu-Val-Lys-Met-Asp-Ala-Glu-Phe-Arg-amide), prepared as 500 (xMin 10% 
DMSO. 
BACE synthetic Swedish mutation peptide substrate, SEVNLDAEFR 
(Acetyl-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-amide), prepared as 500 |iM in 
10% DMSO. 
Cleavage peptide product, DAEFR 
One peptide product of cleavage is (Asp-Ala-Glu-Phe-Arg-amide), prepared as 500 
[jM in 100% DMSO. 
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Sample mix (final volume of 50 i^l) in 10% DMSO. 
substrate (500 ^M) 1 [il 
sample 20 | L I 1 
assay buffer 29 |li1 
HPLC Buffer A 
trifluoroacetic acid (TFA) 0.1% 
The desiring volume was filled with nanopure water. The solution was filtered� 
HPLC Buffer B 
TFA 0.1% 
Acetonitrile 80% 
The remaining volume was filled with nanopure water. The solution was filtered in 
0.22 i^rn filter. 
2.7.10 Reagents for fluorometric assays 
BACE fluorogenic Swedish mutation substrate, FS-1 
(NH2-Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(DABCYL)-Arg-C 
OOH) which was custom synthesized from SynPep (Dublin, CA, USA) and prepared 
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as 500 fiM in 100% DMSO. 
BACE fluorogenic wild-type substrate, FS-2 
(N-acetyl-Arg-Glu(EDANS)-Val-Lys-Met-Asp-Glu-Phe-Arg-Lys(DABCYL)-Arg-ami 
de), which was custom synthesized from Molecular Probes (Eugene, OR, USA) and 
prepared as 500 [M in 100% DMSO. 




The solution was made up to desired volume by PBS. The solution was incubated at 
60�C for 20 minutes to solubilize paraformaldehyde. 
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Chapter 3 Results 
Chapter 3 
Results 
3.1 Expression of BACE in E. coli 
3.1.1 Cloning of truncated human and mouse BACE into pRSET 
The cDNA for human BACE without the transmembrane and pre region, 
prohBACE (refer to Fig. 3-1 A) was amplified by PGR techniques from human brain 
cDNA (in pCMV. SPORT purchased from BRL) using forward primer (hBACE—517F) 
and reverse primer (hBACE_R1833) (The primer sequences were shown in Appendix 
A2). A PGR product of about 1.3kb was amplified and extracted from gel by the 
QIAquick Gel Extraction Kit. 
The cDNA for human BACE without transmembrane, pre and pro region, 
nohBACE (refer to Fig. 3-lA) was amplified by PGR techniques from human brain 
cDNA (in pCMV.SPORT purchased from BRL) using forward primer (hBACE—589F) 
and reverse primer (hBACE_R1833). Fragment of about 1.2kb were amplified and 
extracted from gel by the QIAquick Gel Extraction Kit (Fig. 3-1 A). 
The cDNA of mouse BACE without the transmembrane, pre and pro region, 
designated as nomBACE, was amplified by RT-PCR using total mouse brain RNA as 
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template. The forward primer (mBACE_147F) and reverse primer (inBACE_R1382). 
A PCR fragment of about 1.2kb was amplified and the amplified DNA was extracted 
from gel by the QIAquick Gel Extraction Kit. 
The cDNA of nohBACE and prohBACE were subcloned into vector 
pRSETA (Invitrogen, the plasmid map was shown in Appendix A1-4) at the EcoRI 
and Xhol sites (Fig. 3-1 A). The cDNA of nomBACE was subcloned into vector 
pRSETB at the EcoRI and Nhel sites (Fig. 3-IB). The plasmids were purified by High 
Pure Plasmid Isolation Kit (Roche) and DNA sequencing was performed using T7 
sequencing primer. The results from DNA sequencing showed that prohBACE in 
vector pRSETA (designated as prohBACE-pRSETA) and nohBACE in vector 
pRSETA (designated as nohBACE-pRSETA) had 98% similarity with the published 
human BACE mRNA sequence (GenBank Accession number AF190725) while 
nomBACE in vector pRSETB (designated as nomBACE-pRSETB) had 95% 
similarity with the published mouse BACE mRNA sequence (GenBank Accession 
number AF 190726). After ensuring the nohBACE, prohBACE and nomBACE had 
successively been cloned into pRSET vector, the constructed plasmids were 
transformed into E.coli strain, BL21(DE3)LysS, which is specially designed for 
expression. 
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Fig. 3-1 (A) Digestion product of inserts (nohBACE and prohBACE) and vector 
(pRSETA) by restriction enzyme EcoRI and Xhol and was run in 1% agarose gel. 
Lanel. 500 bp marker. Lane 2. nohBACE cDNA of about 1.2kb. Lane 3. prohBACE 
cDNA of about 1.3kb. Lane 4. pRSETA of about 2.9kb. (B) Digestion product of 
insert, nomBACE and vector (pRSETB) by restriction enzyme EcoRI and Nhel and 
was run in 1% agarose gel. Lane 1. 1 kb marker. Lane 2. Digested pRSETB of about 
2.9kb as indicated by the marker. Lane 3. nomBACE gene of about 1.2kb as indicated 
by the marker. 
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3. J. 2 Expression of BACE in BL21(DE3)LysS cells 
3.1.2.1 Expression of truncated mouse and human BACE in BL21(DE3)LysS cells 
using conventional method 
nomBACE, prohBACE and nohBACE were expressed in E.coli strain, 
BL21(DE3)LysS cells by induction of 0.4 mM IPTG (refer to section 2.2.1), the 
results were shown in Fig. 3-2A and Fig. 3-2B respectively. There was no apparent 
induction of mouse and human BACE when compared the expression profiles of the 
uninduced and induced cells. Much attempt had been tried to express the proteins, 
such as changing the concentration of IPTG, time of induction, expression of different 
clones (data not shown). However, no progress had been made. Finally, a plasmid 
stability test had been done, as described in section 2.2.10. According to the test, for 
stable plasmid, a very small proportion of cells will survive in LB plate with IPTG 
and almost all cells will survive in LB plate with antibiotics. However, the result of 
test showed a large number of cells survived in LB plate with IPTG and very few 
colonies survived in the LB plate with antibiotics. This proved the plasmids 
transformed were unstable or cDNAs transformed were toxic. 
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Fig. 3-2 Coomassie blue stained 15% SDS-PAGE gel of the expression of the mouse 
and human BACE protein using the pRSET expression vector by convention method. 
(A) Lane 1: Protein molecular weight markers (Invitrogen). Lane 2: induction of 
BL21(DE3)LysS cells transformed with nomBACE-pRSETB by 0.4 mM IPTG. Lane 
3: no induction of BL21(DE3)LysS cells transformed with nomBACE-pRSETB. (B) 
Lane 1: Protein molecular weight markers (Invitrogen). Lane 2: uninduced 
BL21(DE3)LysS cells transformed with nohBACE-pRSETA. Lane 3; induction of 
BL21(DE3)LysS cells transformed with prohBACE-pRSETA by 0.4mM IPTG. Lane 
4: induction of BL21(DE3)LysS cells transformed with nohBACE-pRSETA by 
0.4mM IPTG. 
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S. 1.2.2 Expression of truncated mouse and human BA CE in BL21 (DE3)LysS cells 
using modified method 
In order to express the toxic cDNAs，the expression method was modified 
as described in section 2.2.2. BL21(DE3)LysS cells transformed with 
nomBACE-pRSETB was expressed by the modified method. The expression was 
induced by 0.4 mM IPTG. As shown in Fig. 3-3，there was no apparent induction 
when compared the expression profiles of the uninduced cells and induced cells. 
BL21(DE3)LysS cells transformed with nohBACE-pRSETA and 
prohBACE-pRSETA were expressed by the modified method. The expression was 
induced by 0.4 mM IPTG. As shown in Fig. 3-4, the bacterial extracts from clones 
transformed with prohBACE-pRSETA (lane 3) and nohBACE-pRSETA (lane 4) 
over-expressed proteins of � 4 9 kDa and -47 kDa respectively which was absent from 
the control (lane 2). The expressed proteins were extracted in inclusion body ofE.coIi 
using buffer B with 8M urea or buffer D with 6 M guanidine HCl. The proteins were 
refolded by rapid dilution in 10 fold buffer B or 60 fold buffer D. The proteins were 
purified by running His-tag binding column and eluted in buffer B with 0.8 M urea or 
buffer D with 0.1 M guanidine HCL with 200 mM imidazole. For detailed experiment 
methods above, refer to section 2.2. The results are shown in Fig. 3-5. 
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Fig. 3-3 Coomassie blue stained 15% SDS-PAGE gel showing the lack of expression 
of the mouse BACE protein using the pRSETB expression vector. Lane 1: Protein 
molecular weight markers (Invitrogen). Lane 2: cell lysates from BL21(DE3)LysS 
cells transformed with nomBACE-pRSETB without IPTG induction. Lane 3: cell 
lysates from BL21(DE3)LysS cells transformed with nomBACE-pRSETB with 0.4 
mM IPTG induction. 
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Fig. 3-4 Coomassie blue-stained 15% SDS-PAGE of E.coli cell lysates expressed with 
human BACE. Lane 1: Protein molecular weight markers (Invitrogen). Lane 2: cell 
lysates from BL21(DE3)LysS cells transformed with prohBACE-pRSETA without 
IPTG induction. Lane 3: cell lysates from BL21(DE3)LysS cells transformed with 
prohBACE-pRSETA with 0.4 mM IPTG induction. Lane 4: cell lysates from 
BL21(DE3)LysS cells transformed with nohBACE-pRSETA with 0.4 mM IPTG 
induction. Arrows indicated the specific protein bands with molecular sizes consistent 
with the predicted sizes of the recombinant BACE. 
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Fig. 3-5 Coomassie blue stained 15% SDS-PAGE of purified inclusion bodies from 
E.coli cell lysates overexpressed with prohBACE and nohBACE protein. Lane 1. 
Protein molecular weight markers (Invitrogen). Lane 2. extract of inclusion body from 
BL21(DE3)LysS cells transformed with plasmid prohBACE-pRSETA. Lane 3. extract 
of inclusion body from BL21(DE3)LysS cells transformed with plasmid 
nohBACE-pRSETA. Lane 4. prohBACE solublized in 0.8 M urea. LaneS. nohBACE 
solublized in 0.8 M urea. Lane 6. prohBACE solublized in 0.1 M guanidine HCl. 
Lane 7. nohBACE solublized in 0.1 M guanidine HCL 
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3.1.3 Analysis of BACE activity of purified recombinant proteins 
3.1.3.1 Fluorometric analysis 
The BACE activity was measured by the use of a fluorometric assay based 
on the principle of fluorescence resonance energy transfer (FRET). It is based on a 
distance-dependent interaction between the electronic excited states of two dye 
molecules in which excitation is transferred from a donor molecule, the flurorophore 
to an acceptor molecule, the quencher. The longer the distance, the larger the 
fluorescence reading. The peptide contains both fluorophore and quencher at both 
ends and upon hydrolysis of the substrate by BACE, the quenching effect is abolished 
and the fluorescence increases in parallel to the level of hydrolysis (Ermolieff et al., 
2000). 
The fluorophore used was 2-aminoethyl amino-naphthalene-1 -sulfonic acid, 
EDANS with maximum absorption in wavelength of 335nm and maximum emission 
in wavelength of 493 nm. The quencher used was 4-dimethylaminophenylazo benzoic 
acid, DABCYL with maximum absorption in wavelength of 453 nm. The chemical 
structures of EDANS and DABCYL were shown in A3. Two substrates were used 
(refer to section 2.7.10). One synthetic peptide, 
(NH2-RE(EDANS)EVM.DAEFK(DABCYL)R-C00H), FS-1, was derived from the 
APP of "Swedish mutation" (SEVNL/DAEFR) with BACE cleavage site (marked by 
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a slash). The other synthetic peptide, 
(NH2-RE(EDANS)VKMDEFAK(DABCYL)R-amide), FS-2 was derived from the 
wild type APP (SEVKM/DAEFR) with BACE cleavage site (marked by a slash). 
The activity of purified nohBACE and prohBACE extracted in urea and 
guanidine HCL were analysed by the fluorescence assay using method described in 
section 2.5. Controls were prepared in which all proteins were boiled in 98°C for 30 
minutes. 
The fluorescence readings were changed to concentration of fluorophore 
released by the equation of y = 0.57x + 6.48 in the regression line of the standard 
curve in Fig. 3-6. No activity had been detected in the controls as shown by no 
increase in fluorescence reading. Comparing Fig. 3-7A and Fig. 3-7B, all proteins 
preparations had higher activity towards FS-1 than FS-2; Proteins extracted in 
guanidine HCl had higher activity towards both substrates than those extracted in urea; 
nohBACE had higher activity towards both substrates than prohBACE. Activity of 
enzyme stopped when it reach incubation time of 4 hours. 2 jiig of samples were added 
in each assay. As shown in Fig. 3-7A, nohBACE extracted in guanidine HCl, 
prohBACE extracted in guanidine HCl, nohBACE extracted in urea and prohBACE 
extracted in urea had BACE activity of about 19.91, 15.22, 8.11 and 0.72 nmol/mg/hr 
towards FS-1 respectively. In Fig. 3-7B, nohBACE extracted in guanidine HCl, 
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prohBACE extracted in guanidine HCl, nohBACE extracted in urea and prohBACE 
extracted in urea had BACE activity of 8.78, 8.02, 1.81 and 1.12 nmol/mg/hr towards 
FS-2 respectively. 
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Fig. 3-6 Standard curve of EDANS fluorescence (Molecular Probes). Various concentration of 
EDANS was dissolved in assay buffer (section 2.7.7). The curve with fluorescence intensity 
(excitation 350 nm and emission 490 nm) against concentration of fluorophore, EDANS added 
(black circles). The regression was drawn in black solid line and with equation of y = 0.57x + 
6.48. 
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Fig. 3-7 BACE activity of partially purified protein towards 10 |jM FS-1 (A) and 10 
|xM FS-2 (B) was measured by fluorometric method. Activity was measured in terms 
of number of mole of fluorophore released as calculated according to the standard 
curve ofEDANS in Fig. 3-6. Four different samples were assayed. nohBACE purified 
and refolded protein extracted in 6M guanidine HCl (closed circles); prohBACE 
purified and refolded protein extracted in 6M guanidine HCl (open circles); nohBACE 
purified and refolded protein extracted in 8M urea (closed triangle); prohBACE 
purified and refolded protein extracted in 8M urea (open triangle). 
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3.2 Expression of BACE in mammalian cells 
3.2.1 Cloning of full length mouse and human BACE into pCDNA3, 
pCDNA4HisMax 
The cDNA encoding the full coding sequence of mouse BACE was 
amplified by RT-PCR using total mouse brain RNA as template. The forward primer 
(mBACE一423F) and reverse primer (mB ACE_1940R) were synthesized according to 
the published sequence(GenBank Accession number AF190726). Consistent with the 
predicted size of mouse BACE cDNAs, a DNA fragment of about L6kb was 
amplified and the amplified DNA was extracted from gel by the QIAquick Gel 
Extraction Kit. 
By similar approach, the cDNA encoding the full coding sequence of 
human BACE was amplified from human brain cDNA (in pCMV. SPORT purchased 
from BRL) using forward primer (hBACE_448) and reverse primer (hBACE—1946R) 
were synthesized according to the published sequence(GenBank Accession number 
AF 190725). Consistent with the predicted size of human BACE cDNAs, a DNA 
fragment of about 1.6kb was amplified and the amplified DNA was extracted from gel 
by the QIAquick Gel Extraction Kit. 
The cDNAs were first cloned into vector pBluescript KS II- (Stratagene, the 
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plasmid map was shown in Appendix Al-1) at restriction site between EcoRI and 
Xhol (Fig. 3-8A and Fig. 3-8B). After confirming the identities of BACE by partial 
DNA sequencing of positive clones, the cDNA of mouse BACE was subcloned into 
mammalian expression vectors, pCDNA3 (Invitrogen, the plasmid map was shown in 
Fig. Al-2) and pCDNA4HisMaxC (Invitrogen, the plasmid map was shown in Fig. 
Al-3). The cDNA of human BACE was subcloned into vectors pCDNAS and 
pCDNA4HisMaxA. The plasmids were purified by High Pure Plasmid Isolation Kit 
(Roche). The recombinant plasmids were further confirmed by DNA sequencing 
using T3 and T7 sequencing primers. The results from DNA sequencing showed that 
mBACE in vector pCDNAS (designated as mBACE-pCDNA3) and vector 
pCDNA4HisMaxC (designated as mBACE-pCDNA4HisMaxC) had 99% similarity 
with the published mouse BACE mRNA sequence (GenBank Accession number 
AF 190726), while the human BACE in vector pCDNA3 (designated as 
hBACE-pCDNA3) and pCDNA4HisMaxA (designated as 
hBACE-pCDNA4HisMaxA) had 98% similarity with the published human BACE 
mRNA (GenBank Accession number AF190725). 
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Fig. 3-8 (A) Digestion product of insert, total mouse BACE and vectors (pBluescript 
KS II-) by restriction enzyme EcoRI and Xhol and was run in 1% agarose gel. Lane 1. 
1 kb marker. Lane 2. Digested mBACE of about 1.6kb as indicated by the marker. 
Lane 3. Digested pBluescript KS II- of about 2.9kb as indicated by the marker. (B) 
Digestion product of insert, hBACE and vector, pBluescript KS II- by restriction 
enzyme EcoRI and Xhol and was run in 1% agarose gel. Lane 1. Ikb marker. Lane 2. 
Digested total human BACE gene of about 1.6kb as indicated by the marker. Lane 3. 
Digested pBluescript KS 11- of about 2.9kb as indicated by the marker. 
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3.2.2 Transient transfection 
The constructed mBACE-pCDNAS, mBACE-pCDNA4HisMaxC, 
hBACE-pCDNA3 and hBACE-pCDNA4HisMaxA were transiently transfected into 
mammalian cell line, Chinese hamster ovary (CHO) cells using Lipofectamine 
transfection method, as described in section. 2.3.1. 
The transfection efficiency was estimated by calculating the percentage of 
stained cells, which has p-galactosidase activity, in CHO cells transfected with 
pCDNA4HisMax/acZ using the same method as in section 2.3.2. The result was 
shown in Fig. 3-9. About 20% of cells were transfected. No transfection efficiency 




Fig. 3-9 The transfection efficiency of pCDNA4HisMax was estimated by 
P-galactosidase activity under 200 x light microscope. CHO cells transiently 
transfected with plasmid pCDNA4HisMax/acZ. 
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3.2.2.1 Western blot analysis 
The membrane extracts were obtained from the transiently transfected cells, 
as described in section 2.3.4. To determine the expression of BACE in the transiently 
transfected cells, Western blotting was performed. Western blotting was carried out 
with two polyclonal antibodies, hBACE 122 and hBACE485 separately, according to 
section 2.2.9. Sensitivity of hBACE485 was low as signals will only be detected after 
incubation of 4 hours with BCIP and NET in buffer 3. hBACE485 binded to BACE 
expressed with high specificity, as no other non-specific binding was detected in Fig. 
3-1 OB. No signal was detected in the untransfected cells, and weak protein band with 
molecular weight approximately 54 kDa were detected in cells transfected with 
mBACE-pCDNA3, mBACE-pCDNA4HisMaxC, hBACE-pCDNA3 and 
hBACE-pCDNA4HisMaxA. And a relatively strong signal was detected in cells 
transfected with mBACE-pCDNA4HisMaxC. However, there was no signal at all 
when using hBACE 122 (result not shown). 
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Fig. 3-10 Western blot analysis on membrane extracts of CHO cells transiently 
transfected with mBACE or hBACE in mammalian expression vectors with 
hBACE485 antibody. Membrane extracts obtained from transiently transfected cell 
lines were separated in SDS-PAGE (A) and were transferred to a PVDF membrane for 
Western blot analysis (B). Lane 1. Protein molecular weight markers (Invitrogen). 
Lane 2. Untransfected cells. Lane 3. Cells transiently transfected with 
hB ACE-pCDNA3. Lane 4. Cells transiently transfected with 
hB ACE-pCDN A4HisMaxA. Lane 5. Cells transiently transfected with 
mB ACE-pCDNA3. Lane 6. Cells transiently transfected with 
mB ACE-pCDN A4HisMaxC. A faint immunoreactive protein of 54 kDa was 
detected as indicated. 
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3.2.2.2 Fluorometric analysis 
The activity of membrane extracts from cells transiently transfected with 
mBACE-pCDNAS, mBACE-pCDNA4HisMaxC, hBACE-pCDNA3 and 
hBACE-pCDNA4HisMaxA were analysed by the fluorometric assay using method 
described in section 2.5. Untransfected cell extracts were used as control. 
The fluorescence readings were changed to concentration of fluorophore 
released by the equation of y = 0.57x + 6.48 in the regression line of the standard 
curve in Fig. 3-6. As shown in Fig. 3-11A and Fig 3-1 IB, all membrane extracts had 
higher activity towards FS-1 than FS-2; Cells transiently transfected with mBACE 
had higher activity towards both substrates than cells transiently transfected with 
hBACE constructed in the same vector, it is also shown that the constructs in 
pCDNAHisMax generally had higher activity towards both substrates than cells 
transiently transfected in constructs of pCDNA3. There were activity from the 
membrane extracts of untransfected cells. The activity in terms of concentration of 
fluorophore released due to the transfected genes only were obtained by deducting the 
activity of transfected cells by those of untransfected cells in each time intervals. 2 jiig 
of samples were added in each assay. In Fig. 3-llA, membrane extracts of cells 
transiently transfected with mBACE-pCDNA3, hBACE-pCDNA3, 
mBACE-pCDNA4HisMaxC and hBACE-pCDNA4HisMaxA had BACE activity of 
8 8 
about 6.01，1.64，8.00 and 5.30 nmol/mg/hr towards FS-1 respectively. In Fig. 3-1 IB, 
membrane extracts of cells transiently transfected with mBACE-pCDNA3, 
hBACE-pCDNA3, inBACE-pCDNA4HisMaxC and hBACE-pCDNA4HisMaxA had 
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Fig. 3-11 BACE activity of membrane extracts from cells transfected with various 
mammalian expression vectors towards 10 joM FS-1 (A) and 10 [\M FS-2 (B) was 
measured by fluorometric method. Activity was measured in terms of number of mole 
of fluorophore released as calculated according to the standard curve of EDANS in 
Fig. 3-6. Four different samples were assayed. Membrane extracts obtained from cells 
transfected with mBACE-pCDNA3 (closed circles), hBACE-pCDNA3 (open circles), 




The fluorometric analysis only determined the rate of cleavage of substrate 
deriving from Swedish mutation or wild type peptide. In order to determine the 
cleavage was correctly cleaved at NL site, analytical HPLC was performed. Two 
peptides substrates and one peptide product were used (refer to section 2.7.9). One 
synthetic peptide, SEVNLDAEFR, was derived from the APP of "Swedish mutation" 
rSEVNL/DAEFR) with BACE cleavage site (marked by a slash). The other synthetic 
peptide, EVKMDAEFR, was derived from the wild type APP rSEVKM/DAEFR) 
with BACE cleavage site (marked by a slash). As seen from cleavage of above, one 
common cleavage product, DAEFR, was also synthesized. 
HPLC was performed as section 2.4. The three peptides were run in the 
HPLC as standard as shown in Fig. 3-12. Swedish mutation peptide substrate, 
SEVNLDAEFR was eluted in 15.7 minutes. Wild type peptide substrate, 
EVKMDAEFR was eluted in 15.1 minutes. Common product of cleavage, DAEFR 
was eluted in 12.1 minutes. 
Three samples will be analysed, membrane extracts from untransfected cells; 
membrane extracts from cells transiently transfected with mBACE-pCDNA3 and 
membrane extracts from cells transiently transfected with 
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mBACE-pCDNA4HisMaxC. A control was set up for each sample, and was treated 
similarly as those of samples unless they were heated for 30 minutes before 
incubation with substrates. 2 \ig of samples were added in each assay. And two 
peptide substrates, SEVNLDAEFR and EVKMDAEFR were incubated with the 
samples and their controls. 
No product peak of DAEFR at 12.1 minutes were observed in the 12 
HPLCs with the exception of incubation of SEVNLDAEFR with membrane extracts 
from cells transfected with mBACE-pCDNA4HisMaxC as shown in Fig. 3-13L. This 
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Fig. 3-12 HPLC chromatography of peptides used as BACE substrates and their 
cleaved product. The peptide substrates were EVKMDAEFR (wild type substrate) 
eluted at 15.1 minutes; SENYLDAEFR (Swedish mutation substrate) eluted at 15.7 
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Fig. 3-13 Chromatograms of RP-HPLC assay. 10 jxM peptide substrate and 2 jig 
sample were mixed in assay buffer. The reaction was stopped by boiling and storing 
in -20�C. (A) Membrane extracts from untransfected cells were boiled for 30 minutes 
before incubating with substrate EVKMDAEFR. (B) Membrane extracts from 
untransfected cells incubating with substrate EVKMDAEFR. 
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Fig. 3-13 (C) Membrane extracts from untransfected cells were boiled for 30 minutes 
before incubating with substrate SEVNLDAEFR. (D) Membrane extracts from 
untransfected cells incubating with substrate SEVNLDAEFR. 
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Fig. 3-13 (E) Membrane extracts from cells transiently transfected with 
mBACE-pCDNA3 were boiled for 30 minutes before incubating with substrate 
EVKMDAEFR. (F) Membrane extracts from cells transiently transfected with 
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Fig. 3-13 (G) Membrane extracts from cells transiently transfected with 
mBACE-pCDNA3 were boiled for 30 minutes before incubating with substrate 
SEVNLDAEFR. (H) Membrane extracts from cells transiently transfected with 
mBACE-pCDNA3 incubating with substrate SEVNLDAEFR. 
9 7 




- 八 ^ _ ^ — “ 
o . o v v . . — 





11.50 ‘ ‘ ialoD ‘ ’ u'sd ‘ ‘ blod ‘ ‘ iilsd ‘ ‘ i4lod ‘ ‘ IAISO ’ ‘ is'do • _ islso ‘ ‘ ISIDO ‘ ‘ is! so • 
X Hlavt«» 
O.M- i j 
。"： EVKMDAEFR 
。 ， I 
0 - M -






ulsd ‘ ‘ ialoD ‘ ‘ ia^sd ‘ ’ blod ‘ ‘ ialsd ‘ 14！.od “ itlso ‘ ‘ iisJoi ‘ _ islso ‘ ‘ ieloo ‘ ‘ islsd ‘ 
J >UBUt,» 
Fig. 3-13 (I) Membrane extracts from cells transiently transfected with 
mBACE-pCDNA4HisMaxC were boiled for 30 minutes before incubating with 
substrate EVKMDAEFR. (J) Membrane extracts from cells transiently transfected 
with mBACE-pCDNA4HisMaxC incubating with substrate EVKMDAEFR. 
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Fig. 3-13 (K) Membrane extracts from cells transiently transfected with 
mBACE-pCDNA4HisMaxC were boiled for 30 minutes before incubating with 
substrate SEVNLDAEFR. (L) Membrane extracts from cells transiently transfected 
with mBACE-pCDNA4HisMaxC incubating with substrate SEVNLDAEFR. 
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3.2.3 Stable transfection 
As from the result of the Western blotting, fluorometric and HPLC analysis, 
the transient transfection of CHO cell line did not express BACE significantly as 
compared to controls. Hence, efforts had been made to develop CHO cells stably 
transfected with mBACE-pCDNA3 and hBACE-pCDNA3. 
pCDNA3 contains neomycin resistance gene for selection of stable 
transfectants in mammalian cells against antibiotics, geneticin G418. Generation of 
stable transfected cell lines were transiently transfected with mB ACE-pCDNA3 and 
hBACE-pCDNA3 as described in section 2.3.1, then the cells that stably transfected 
with plasmids were selected by antibiotics, geneticin G418, as described in section 
2.3.3. 
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3.2.3.1 Western blot analysis 
To determine the expression of BACE in the stably transfected cell lines, 
Western blotting was carried out with polyclonal antibody, hBACE485, according to 
section 2.2.9. Sensitivity of hBACE485 was low as signals will be detected after 
incubation of 4 hours with BCIP and NBT in buffer 3. hBACE485 binded to BACE 
expressed with high specificity, as no other non-specific binding was detected in Fig. 
4.7B. No signal was detected in the untransfected cells, and strong signals of about 61 
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Fig. 3-14 Recognition of BACE gene on cells stably transfected with mBACE or 
hBACE gene by primary antibody hBACE485 in Western blotting. Membrane 
extracts obtained from stably transfected cell lines were separated in SDS-PAGE (A) 
and were transferred to a PVDF membrane for Western blot analysis (B) Lane 1. 
Protein molecular weight markers (Invitrogen). Lane 2. Cells stably transfected with 
hBACE-pCDNA3. Lane 3. Cells stably transfected with mBACE-pCDNA3. Lane 4. 
Untransfected cells. 
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3.2.3.2 Fluorometric analysis 
The activity of membrane extracts from cells stably transfected with 
mBACE-pCDNAS and hBACE-pCDNA3 were analysed by the fluorometric assay 
using method described in section 2.5. 
As shown in Fig. 3-15A and Fig 3-15B，all membrane extracts had higher 
activity towards FS-1 than FS-2; Cells stably transfected with mBACE had higher 
activity towards both substrates than cells stably transfected with hBACE. There were 
activity from membrane extract of untransfected cells. The activity in terms of number 
of mole of fluorophore released due to the transfected genes only were obtained by 
deducting the activity of transfected cells by those of untransfected cells in each time 
intervals. Activity of enzyme reached a plateau at 4 hours of incubation. 2 |Lig of 
samples were added in each assay. In Fig. 3-15A, membrane extracts of cells stably 
transfected with mBACE-pCDNAS and hBACE-pCDNA3 had BACE activity of 
about 23.25 and 16.06 nmol/mg/hr towards FS-1 respectively. In Fig. 3-15B, 
membrane extracts of cells stably transfected with mBACE-pCDNAS and 
hBACE-pCDNA3 had BACE activity of about 10.58 and 8.29 nmol/mg/hr towards 
FS-2 respectively. 
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Fig. 3-15 BACE activity of membrane extracts from cells transfected with mBACE 
and hBACE in vector pCDNA3 towards 10 |iM FS-1 (A) and 10 ^M FS-2 (B) was 
measured by fluorometric method. Activity was measured in terms of number of mole 
of fluorophore released as calculated according to the standard curve of EDANS in 
Fig. 3-6. Two different samples were assayed. Membrane extracts obtained from cells 
stably transfected with mBACE-pCDNAS (closed circles), hBACE-pCDNA3 (open 
circles). 
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3.2.3.3 HPLC 
HPLC was performed as described in section 2.4. Three samples were 
analysed, membrane extracts from untransfected cells, cells stably transfected with 
mBACE-pCDNA3 and hBACE-pCDNA3. A control was set up for each sample, and 
was treated similarly as those of samples unless they were heated for 30 minutes 
before incubation with substrates. 2 |Lig of samples were added in each assay. And two 
peptide substrates, SEVNLDAEFR and EVKMDAEFR were incubated with the 
samples and their controls. 
No product peak of DAEFR at 12.1 minutes was observed in the membrane 
extracts from untransfected cells either in the samples or boiled controls towards both 
substrates, as shown in Fig. 4.9A-D. No product peak of DAEFR at 12.1 minutes was 
observed in the boiled control of membrane extracts from cells stably transfected with 
mBACE-pCDNA3 and hBACE-pCDNA3 towards both substrates, as shown in Fig. 
3-16 E, G, I, K. However, product peak of DAEFR at 12.1 minutes and the substrate 
peaks reduced significantly were observed in membrane extracts from cells 
transfected with mBACE-pCDNA3 and hBACE-pCDNA3 towards both substrates, as 
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Fig. 3-16 Chromatograms of RP-HPLC assay. 10 |aM peptide substrate and 2 |xg 
sample were mixed in assay buffer. The reaction was stopped by boiling and storing 
in —20�C. (A) Membrane extracts from untransfected cells were boiled for 30 minutes 
before incubating with substrate EVKMDAEFR. (B) Membrane extracts from 
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Fig. 3-16 (C) Membrane extracts from untransfected cells were boiled for 30 minutes 
before incubating with substrate SEVNLDAEFR. (D) Membrane extracts from 
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Fig. 3-16 (E) Membrane extracts from cells stably transfected with mBACE-pCDNAS 
were boiled for 30 minutes before incubating with substrate EVKMDAEFR. (F) 
Membrane extracts from cells stably transfected with mBACE-pCDNAS incubating 
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Fig. 3-16 (G) Membrane extracts from cells stably transfected with 
mBACE-pCDNAS were boiled for 30 minutes before incubating with substrate 
SEVNLDAEFR. (H) Membrane extracts from cells stably transfected with 
mBACE-pCDNA3 incubating with substrate SEVNLDAEFR. 
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Fig, 3-16 (I) Membrane extracts from cells stably transfected with hBACE-pCDNA3 
were boiled for 30 minutes before incubating with substrate E V K M D A E F R (J) 
Membrane extracts from cells stably transfected with hBACE-pCDNA3 incubating 
with substrate EVKMDAEFR. 
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Fig. 3-16 (K) Membrane extracts from cells stably transfected with hBACE-pCDNA3 
were boiled for 30 minutes before incubating with substrate SEVNLDAEFR. (L) 
Membrane extracts from cells stably transfected with hB ACE-pCDN A3 incubating 
with substrate SEVNLDAEFR. 
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3.2.3.4 Immunohistochemistry 
Polyclonal antibody hBACE485 purchased from ALEXIS was used as 
primary antibody used in immunohistochemistry. The cells were permealized with 
0.1% triton X in PBS. Very few signals were detected in the untransfected cells, 
strong signals were detected in the cells stably transfected with mBACE-pCDNAS 
and hBACE-pCDNA3, while stronger signals were detected in cells stably transfected 
with mB ACE-pCDNA3. Most of cells had much stronger signals outside the nucleus. 
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Wf. Fig. 3-17 Immunohistochemistry of BACE gene from (A) untransfected cells, (B) cells stably transfected with mBACE-pCDNAS and (C) cells stably transfe ted withhBACE-pCDNA3 using BACE485. The cells were unpermelised. Sc l  bar was 10mM. 113 
Fluorometric analysis HPLC analysis (% of Immunohistochemistry Western Blot Analysis  
(nmol/mg/hr) substrate cleaved) (intensity of signal) (intensity of signal) 




CDNAS 6.01 2.07 0.00% 0.00% + 
hBACE-pC 
DNA3 1.64 1.84 0.00% 0.00% + 
mBACE-p 
CDNA4His 
MaxC 8.00 3.12 0.00% 0.00% + 
hBACE-pC 
DNA4His • 




CDNAS 23.25 10.58 66.67% 85.71% +++++ +++ 
hBACE-pC 





pRSETA 8.11 1.81 
prohBACE-




pRSETA 19.11 8.78  
prohBACE- ” 
pRSETA I 15.22 8.02 not applicable  
* E.coli. expression was failed using vector nomBACE-pRSETB 
Table 2 Summary of results of different assays using different vectors transformed and 
transfected into E.coli cells, BL21(DE3)LysS and mammalian cells, CHO cells 
respectively 
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Chapter 4 Discussions 
Chapter 4 
Discussion 
Based on the sequencing results, the cloned BACE cDNAs have 
discrepancy with the published sequences, such as nomBACE and nohBACE had 
95% and 98% identity with the reported sequences. The discrepancy was due to the 
wrong interpretations of computer, for example, some repeated signals, like CCCC, 
the computer may recognize it as CCC. The signals generated from the computer was 
checked manually using the program "chromas", the identity of sequences with the 
reported sequences were confirmed to 100% before transforming into 
BL21(DE3)LysS for expression, so as to avoid frameshift and wrongly encoded 
sequences occur. 
In this study, the truncated forms of BACE without the transmembrane and 
C-terminal domains were demonstrated to be functionally expressed in prokaryotic 
expression system. Two constructs of BACE cDNAs were designed: one construct 
cDNA lacked of the coding sequence of the putative pre-domain; whereas the other 
lacked the pre- and pro-domain. ProhBACE and nohBACE had molecular size of 49 
and 47 kDa as shown in SDS-PAGE in Fig. 3-4. According to analysis of protein size 
by SWISS-PROT, prohBACE and nohBACE protein had molecular weight of 48.78 
and 46.14 kDa respectively. The size of protein expressed matched with the protein 
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size determined. 
Using fluorometric analysis, Ermolieff et al. (2000) has determined the 
activity of BACE protein expressed from BL21(DE3) cells. Using synthetic Swedish 
mutation substrate, the activity of nohBACE was about 3.75 fold of that of 
prohBACE. Using synthetic wild-type substrate, the activity of nohBACE was about 
1.60 fold of that of prohBACE. In this study, using synthetic Swedish mutation 
substrate, FS-1, the activity of nohBACE was about 221 fold of that of prohBACE. 
Using synthetic wild-type substrate, FS-2, the activity of nohBACE was about 1.90 
fold of that of prohBACE. Comparing the result of Ermolieff et al. (2000) with ours, 
two similarity were found. First, the enzyme activity of BACE without the 
pro-domain (nohBACE) was higher than the one with the pro-domain (prohBACE). 
Secondly, the catalytic activity of both nohBACE and prohBACE towards FS-1 were 
higher than FS-2. The next two paragraphs will discuss the two similarity in details. 
Like other aspartic proteases, the pro-domain blocks the entrance to the 
respective active-site clefts (James and Sielecki, 1986; Hartsuck et a/., 1992; Moore et 
aL, 1995). Likewise, it has previously been suggested that BACE is synthesized as 
zymogen with an inactive form containing the pro-domain (Bennett et cd., 2000; 
Haniu et aL’ 2000). The lower catalytic activity of proHBACE suggested that the 
conformation of its pro domain exists in two equilibrium forms: one with the active 
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site ‘open’ and other with the active site ‘closed’ by virtue of a propeptide blockade 
(ErmoliefF et al., 2000). The catalytic activity of nohBACE was higher than 
prohBACE towards FS-1 and FS-2. This can be explained by the removal of the pro 
domain, leading to the formation of constitutively active enzyme. 
The catalytic activity of both nohBACE and prohBACE towards FS-1 were 
higher than FS-2. This is consistent with the finding that BACE cleave synthetic 
peptides mimicking Swedish mutation APP than those peptides mimicking wild type 
APP (Vassar et al., 1999; Yan et al., 1999; ErmoliefF et al., 2000). The partial 
sequence of FS-2, which mimic wild type peptide, was EVKM*DA. Mutations of KM 
to NL at P2-P1, resulting EVNL*DA, the so-called Swedish mutation, were present in 
FS-1. These residues were labeled P4-P3-P2-P1/P1'-P2' in standard protease 
nomenclature with cleavage between PI and PI' marked by *. In the models of BACE 
with APP-derived substrates as shown in Fig. 4-1, both the PI leucine residue and PI 
methionine residue on FS-1 and FS-2 make good hydrophobic contacts with Leu91, 
Tyrl32 and Ilel79. In FS-2, the P2 lysine makes a salt-bridge with BACE at Asp379. 
However, in FS-1, The P2 Asparagine can hydrogen bond to BACE Arg296, which 
hydrogen bonds to the PI' Asp (Sauder et al., 2000). Having a more stable 
enzyme-substrate complex in FS-1 may account for the higher tendency of cleavage 
by BACE. Also various data showed that BACE has specificity for a hydrophobic 
residue at PI (Sauder et al, 2000). 
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Fig. 4-1 Models of BACE with APP-derived substrates. (A) Wild-type substrate 
592-597 of APP 695 (GenBank accession CAA312830.1) with sequence EVKM*DA 
with cleavage of the M-D peptide bond, indicated by an arrow. (B) Swedish mutation 
substrate with P2-P1 sequence of Asn-Leu (red) in place of wild-type Lys-Met 
(sequence EVNL*DA) (Sauder et al., 2000). 
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Activity of protein purified and refolded in 0.1 M guanidine HCl was higher 
than those in 0.8M urea. However this may not be the case, as guanidine HCl and urea, 
which are denaturing agent, still present in the solution. In order to make a 
comparison of the activity of protein extracted in guanidine HCl and urea, all the 
denaturing agent should be removed. 
There had been difficulty in expressing truncated mouse and human BACE 
protein in BL21(DE3)LysS cells. After cloning of truncated mBACE and hBACE 
cDNAs into vector pRSETB and pRSETA respectively, much attempt had been tried 
to express the proteins using conventional method using different conditions, such as 
changing the concentration of IPTG, duration of induction, expression of different 
clones. However, no protein was successfully expressed. Finally, a plasmid stability 
test had been done to determine the level of toxic effect of target gene expression on 
bacterial growth, as described in section 2.2.10. According to the test, for stable 
plasmid, growth is prevented for any cells that have both the inducible gene for T7 
RNA polymerase and a functional target plasmid. However, growth of cells that lack 
plasmid or mutants that have lost the ability to express target DNA is not prevented. 
Hence, less than 2% of cells will survive in LB plate with IPTG, less than 0.01% of 
cells will survive in LB plate with EPTG and antibiotics and almost all cells will 
survive in LB plate with antibiotics (Studier et aL, 1990). The result of test showed a 
large number of cells survived in LB plate with IPTG and very few colonies survived 
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in the LB plate with antibiotics. This proved the plasmids transformed were unstable 
or the genes were toxic. 
If the gene whose product is toxic to the host cells is cloned in the plasmid. 
The level of expression may be such that the plasmid can be maintained but growth of 
the cells is impaired; segregation of cells lacking plasmid may also be increased 
because of decreased copy number or for other reasons. In this situation, cells that 
lack the plasmid can rapidly overgrow the culture whenever selective antibiotic is 
lacking. In the conventional method, the BL21(DE3)LysS cells were allowed to grow 
overnight in the presence of ampicillin before induction, a considerable amount of /5 
-lactamase was secreted into the medium even if it became substantially overgrown 
by cells that lack plasmid. Subcultures were then grown from dilutions of 200 folds 
into fresh ampicillin-containing medium. However, enough ^ -lactamase was present 
in the saturated culture that, even at this dilution, enough remains to destroy all of the 
ampicillin before the cells that lack plasmid can be killed (Studier et al., 1990). 
Therefore, the subculture will grow completely in the absence of selection. This 
explained why no protein was expressed after induction of 0.4 mM IPTG for 3 hours. 
Hence, expression method was modified, as shown in section 2.2.2, in 
which bacterial culture were grown from picking of colonies from agar plate until 
ODeoo of 0.2-0.6. Then the cells were centrifuged immediately so as to remove the old 
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medium containing secreted "-lactamase. The subcultures were grown with 1600 
dilution in fresh medium containing ampicillin until ODeoo of 0.2-0.6 so as to ensure 
the colonies bearing plasmids transformed were properly selected by ampicillin. Then 
the cells were centrifuged and induced for expression by 0.4 mM IPTG in the 
presence of ampicillin. 
Using the modified method, nohBACE and prohBACE were successfully 
expressed. However, nomBACE was failed to express. The nomBACE was cloned 
into vector pRSETB while nohBACE and prohBACE were cloned into vector 
pRSETA. The difference between vector pRSETA and pRSETB was frameshifting of 
one amino acid in multiple cloning sites for expression of protein in suitable reading 
frame. Hence, using these two different vectors should not account for failure of 
expression for nomBACE. One possible reason may be due to the deletion of T7 gene 
10 sequence in pRSETB during cloning. The cDNA of nomBACE was cloned into 
pRSETB at the EcoRI and Nhel sites. Digestion of pRSETB by the two enzymes 
caused the deletion of T7 gene 10 sequence. T7 gene 10 sequence is a transcript 
stabilizing sequence gene 10 of phage T7. T7 gene 10 sequence increases the 
translational efficiency (Olins et al., 1988; Olins and Rangwala, 1989) and stabilizes 
the mRNA (Sprengart et al., 1996). 
The HPLC and fluorometric analysis were done in assay buffer in pH 4.8, 
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refer to section 2.5, 2.6 and 2.7.7, as the activity of BACE was highest in pH of 4 to 5 
(Lin et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). Leupeptin 
(serine/cysteine proteinase inhibitor) and PMSF (serine/cysteine proteinase inhibitor) 
were included in assay buffer in performing HPLC and fluorometric analysis, as 
BACE was not inhibited by these inhibitors (Sinha et al, 1999). With these protease 
inhibitors, the cleavage of substrate by other enzymes could be significantly reduced. 
In mammalian cells, BACE is synthesized as proBACE in the endoplasmic 
reticulum (ER) and then moves to the trans-GoXgi network (TGN) where it rapidly 
loses its pro-domain due to cleavage by proprotein convertase (PC) (Huse et al., 2000; 
Xiang et aL, 2000; Benjannet et al., 2001) and fUrin or a furin-like proprotein 
convertase in mammalian cells (Bennett et al., 2000; Shi et al., 2001). Then BACE 
become mature after 7V-glycosylation (Vassar et al., 1999; Bennett et al., 2000; Walter 
et aL, 2000), especially on the catalytic ectodomain (Bodendorf et aL, 2001; 
Charlwood et al., 2001). Because of iV-glycosylation, the molecular mass of BACE 
expressed in human was greater than expected, and our results showed that the 
hBACE and mBACE expressed in stably cell lines were 55 and 61kDa which is larger 
than hBACE protein with transmembrane region but without pro-domain (5 IkDa). 
In the immunohistochemistry of CHO cells stably transfected with 
inBACE-pCDNA3 and hBACE-pCNDA3, very few signals were detected in the 
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untransfected cells, much higher signals were detected in cells stably transfected with 
mBACE-pCDNAS and hBACE-pCNDA3. Most of signals were detected in the cell 
membrane and cytoplasm. This was consistent with the results that BACE being 
membrane anchoring enzyme and present in secretory pathway, Golgi apparatus, 
trans-GoXgi network (TGN), secretory vesicles and endosomes (Vassar et al., 1999; 
Benjannet et al., 2001; Walter et al, 2001) 
Membrane extracts from cells stably transfected by hBACE-pCDNAS and 
mBACE-pCDNAS preferentially cleaved the P-secretase site from the Swedish 
mutation over wild-type APP in fluorometric analysis as shown in Fig. 3-15, and 
cleaved at the expected position of substrates used in HPLC as BACE as shown in Fig. 
3-16. These were consistent with the results of other groups (Vassar et al., 1999; Yan 
et al., 1999). In the fluorometric analysis, untransfected cells also had activity towards 
FS-1 and FS-2 implied that untransfected cells had expression of BACE, this may be 
due to the fact that most peripherial tissue had low levels of expression of BACE 
(Vassar et al, 1999). 
In transient transfection, expression of BACE in vector pCDNA4HisMax 
was higher than that of pCDNA3. Both pCDNA4HisMax and pCDNA3 contain 
cytomegalovirus (CMV) as promoter for expression. However, pCDNA4HisMax 
contains a QBI SP 163 translational enhancer for increased levels of recombinant 
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protein expression through ribosome recruitment and a cap-independent translational 
mechanism (Stein et al., 1998). Moreover, presence of a large hairpin loop with a 
stability of 115 kcal/mol within the multiple cloning region (between BamHI and NotI) 
in pCDNAS, which likely inhibits translation (Kozak, 1989). Even expression of 
BACE in vector pCDNA4HisMax was better, stable cell lines using vector 
pCDNA4HisMax were not developed as antibiotic zeocin was required to develop 
stable cell line with vector pCDNA4HisMax. At that time, there was no zeocin in our 
laboratory and making new order of it consumes time. Because of time constraint, 
only cell lines with vector pCDNAS were generated. 
The expression of mBACE was better than hBACE in CHO cells as shown 
by fluorometric analysis in Fig. 3-11 and Fig. 3-15, immunohistochemistry in Fig. 
3-17. Even mBACE had 93% sequence identity with hBACE. One possible 
explanation was that Chinese Hamester Ovary (CHO) cells was a mouse cell line, the 
cellular processing of mBACE in CHO cells make the protein more functional. If that 
is the case, a reverse situation may occur if mBACE and hBACE were expressed in 
human cell lines, such as Human Embryonic Kidney (HEK) 293 cells. 
Using RP-HPLC, Vassar et al. (1999) has demonstrated that hBACE protein 
purified from stably transfected 293T cells had activity of 9 nmol/min/mg against 30 
|iM synthetic wild-type peptide with sequence 
1 2 4 
TTRPGSGLTNIKTEEISEVKMDAEFRHDK(dnp)G in a 50 |LI1 assay. Their activity 
was 60 fold of that of membrane extracts from CHO cells stably transfected with 
hBACE-pCDNA3 (8.29 nmol/hr/mg) that we have performed. The difference may be 
due to the fact that the expressed hBACE protein in membrane extract has not been 
purified yet. 
In order to develop a screening assay of inhibitor of BACE, a better 
expression system and a more sensitive assay method were employed. E.coli system 
was chosen to express protein for developing screening assay for inhibitor of BACE 
as E.coli can produce larger quantity of protein in a relatively short time that 
mammalian cells. nohBACE extracted in guanidine HCl will be used to screen for 
inhibitor of BACE as nohBACE had higher activity than prohBACE and nohBACE 
had higher activity when extracted in guanidine HCl than those extracted in urea. 
Fluorometric analysis will be employed as assay method to screen inhibitor of BACE 
as fluorometric analysis was able to analyze large amount of samples in a shorter time 
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A2 Primer lists 
1. Full length human BACE forward PCR primer with EcoRI site (hBACE_448F) 
5’-GTGAATTCC CAC CAT GGC CCA AGC C-3, 
2. pro hBACE forward PCR primer with Xhol site (hBACE_517F) 
5,-CGC TCGAGA CCC AGC ACG GCA TCC G-3, 
3. nohBACE forward PCR primer with Xhol site (hBACE_589F) 
5,-GGC TCGAGACCG ACGAAGAGC CCG-3' 
4. prohBACE and nohBACE reverse PCR primer with EcoRI site (hBACE Rl 833) 
5,-GCGAArTCA ATA GGC TAT GGT CAT GAG-3' 
5. Full length human BACE reverse PCR primer with Xhol site (hBACE Rl 946) 
5,-GCC TCGAGG GCC TCC TCA CTT CAG CAG GG-3, 
6. Full length mouse BACE forward PCR primer with EcoRI site (mBACE_423F) 
S'-GCGAATTCC TCA CTA TGG CCC CGG-3' 
7. Full length mouse BACE reverse PCR primer with Xhol site (mBACE Rl 940) 
5,-GGC TCGAGG CCT CCT TAC TTC AGC AG-3, 
8. nomBACE forward PCR primer with Nhel site (mBACE_147F) 
5'-CTG GCT AGC GAG ACG GAC GAG GAA T-3, 
9. nomBACE forward PCR primer with EcoRI site (mBACE Rl3 82) 
5^-GCGAATTCT TAG GTC ATA AGT GTT GAC-3' 
clxxxi 
A ㈠ 普 � 仏 
B � N 
SO3 
Fig. A3 Chemical structure of fluorophore and quench used in fluorometric assay. (A) 
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